Skip to content | Skip to institutional links

Common menu bar links

Institutional links

INFECTIOUS DISEASE SURVEILLANCE
in Canadian Federal Penitentiaries 2005-2006

Warning This Web page has been archived on the Web.

Appendix A:
Human Immunodeficiency Virus (HIV)

Table A.1.i: HIV Screening Antibody Tests among ALL Inmates in Canadian
Federal Penitentiaries, IDSS^† 2005-2006
Population Tested	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC
Population Tested	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS) 1 – Number of new admissions (new warrants of committal) for the calendar year. 2 – Inmate population as of January 1^st 3 – Flow through population (inmates in CSC January 1^st plus all new admissions)
New Admissions¹	576	572	1,062	966	1,389	1,389	1,351	1,564	508	588	4,819	5,079
Number of Tests Performed	309	324	498	467	762	934	733	841	116	79	2,418	2,645
Proportion of All New Admissions Receiving Test (%) (Testing Uptake)	53.6%	56.6%	46.9%	48.3%	54.9%	67.2%	54.3%	53.8%	22.8%	13.4%	50.2%	52.1%
Number of New Positive HIV Test Reports	1	1	1	2	3	2	1	2	1	0	7	7
New Positive HIV Test Reports as Proportion of Tests Performed (%) (test positivity)	0.09%	0.31%	0.20%	0.43%	0.39%	0.21%	0.14%	0.24%	0.86%	0.00%	0.29%	0.26%
General Population²	1,168	1,292	3,033	3,283	3,295	3,592	2,900	3,139	1,826	1,974	12,222	13,280
Number of Tests Performed	591	494	845	734	654	729	1,069	962	529	591	3,688	3,510
Proportion Of All General Population Inmates Receiving Test (%) (Testing Uptake)	50.6%	38.2%	27.9%	22.4%	19.8%	20.3%	36.9%	30.6%	29.0%	29.9%	30.2%	26.4%
Number of New Positive HIV Test Reports	1	0	1	2	1	0	2	3	2	3	7	8
New Positive HIV Test Reports as Proportion of Tests Performed (%) (Test Positivity)	0.17%	0.00%	0.12%	0.27%	0.15%	0.00%	0.19%	0.31%	0.38%	0.51%	0.19%	0.23%
Total³	1,744	1,864	4,095	4,249	4,684	4,981	4,251	4,703	2,334	2,562	17,041	18,359
Number of Tests Performed	900	818	1,343	1,201	1,416	1,663	1,802	1,803	645	670	6,106	6,155
Proportion of All Inmates Receiving Test (%) (Testing Uptake)	44.9%	43.9%	32.8%	28.3%	30.2%	33.4%	42.4%	38.3%	27.6%	26.2%	35.8%	33.5%
Number of New Positive HIV Test Reports	2	1	2	4	4	2	3	5	3	3	14	15
New Positive HIV Test Reports as Proportion of All Tests Performed (%) (Test Positivity)	0.22%	0.12%	0.15%	0.33%	0.28%	0.12%	0.17%	0.28%	0.47%	0.45%	0.23%	0.24%

Table A.1.ii: HIV Screening Antibody Tests among FEMALE Inmates in
Canadian Federal Penitentiaries, IDSS^† 2005-2006
Population Tested	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC
Population Tested	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS) 1 – Number of female new admissions (new warrants of committal) for the calendar year. 2 – Female Inmate population as of January 1^st 3 – Flow through population (inmates in CSC January 1^st plus all new admissions)
New Admissions¹	42	39	35	39	74	90	99	95	20	40	270	303
Number of Tests Performed	23	24	31	44	113	100	79	127	5	18	251	313
Proportion of All New Admissions Receiving Test (%) (Testing Uptake)	54.8%	61.5%	88.6%	112.8%	152.7%	111.1%	79.8%	133.7%	25.0%	45.0%	93.0%	103.3%
Number of New Positive HIV Test Reports	0	0	1	2	1	0	1	0	0	0	3	2
New Positive HIV Test Reports as Proportion of Tests Performed (%) (Test Positivity)	0.00%	0.00%	3.23%	4.55%	0.88%	0.00%	1.27%	0.00%	0.00%	0.00%	1.20%	0.64%
General Population²	40	60	70	82	104	104	126	146	47	53	387	445
Number of Tests Performed	21	46	10	10	5	8	79	94	30	30	145	188
Proportion of All General Population Inmates Receiving Test (%) (Testing Uptake)	52.5%	76.7%	14.3%	12.2%	4.8%	7.7%	62.7%	64.4%	63.8%	56.6%	37.5%	42.2%
Number of New Positive HIV Test Reports	0	0	0	0	0	0	0	0	0	0	0	0
New Positive HIV Test Reports as Proportion of Tests Performed (%) (Test Positivity)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total³	82	99	105	121	178	194	225	241	67	93	657	748
Number of Tests Performed	44	70	41	54	118	108	158	221	35	48	396	501
Proportion of All Inmates Receiving Test (%) (Testing Uptake)	53.7%	70.7%	39.0%	44.6%	66.3%	55.7%	70.2%	91.7%	52.2%	51.6%	60.3%	67.0%
Number of New Positive HIV Test Reports	0	0	1	2	1	0	1	0	0	0	3	2
New Positive HIV Test Reports as Proportion of All Tests Performed (%) (Test Positivity)	0.00%	0.00%	2.44%	3.70%	0.85%	0.00%	0.63%	0.00%	0.00%	0.00%	0.76%	0.40%

Table A.1.iii: HIV Screening Antibody Tests among MALE Inmates in
Canadian Federal Penitentiaries, IDSS^† 2005-006
Population Tested	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC
Population Tested	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS) 1 – Number of male new admissions (new warrants of committal) for the calendar year. 2 – Male Inmate population as of January 1^st 3 – Flow through population (inmates in CSC January 1^st plus all new admissions)
New Admissions¹	534	533	1,027	927	1,248	1,299	1,252	1,469	488	548	4,549	4,776
Number of Tests Performed	286	300	467	423	649	834	654	714	111	61	2,167	2,332
Proportion of All New Admissions Receiving Test (%) (Testing Uptake)	53.6%	56.3%	45.5%	45.6%	52.0%	64.2%	52.2%	48.6%	22.7%	11.1%	47.6%	48.8%
Number of New Positive HIV Test Reports	1	1	0	0	2	2	0	2	1	0	4	5
New Positive HIV Test Reports as Proportion of Tests Performed (%) (Test Positivity)	0.35%	0.33%	0.00%	0.00%	0.31%	0.24%	0.00%	0.28%	0.90%	0.00%	0.18%	0.21%
General Population²	1,128	1,232	2,963	3,201	3,191	3,488	2,774	2,993	1,779	1,921	11,835	12,835
Number of Tests Performed	570	448	835	724	649	721	990	868	499	561	3,543	3,322
Proportion of All General Population Inmates Receiving Test (%) (Testing Uptake)	50.5%	36.4%	28.2%	22.6%	20.3%	20.7%	35.7%	29.0%	28.0%	29.2%	29.9%	25.9%
Number of New Positive HIV Test Reports	1	0	1	2	1	0	2	3	2	3	7	8
New Positive HIV Test Reports as Proportion of Tests Performed (%) (Test Positivity)	0.18%	0.00%	0.12%	0.28%	0.15%	0.00%	0.20%	0.35%	0.40%	0.53%	0.20%	0.24%
Total³	1,662	1,765	3,990	4,128	4,439	4,787	4,026	4,462	2,267	2,469	16,384	17,611
Number of Tests Performed	856	748	1,302	1,147	1,298	1,555	1,644	1,582	610	622	5,710	5,654
Proportion of All Inmates Receiving Test (%) (Testing Uptake)	51.5%	42.4%	32.6%	27.8%	29.2%	32.5%	40.8%	35.5%	26.9%	25.2%	34.9%	32.1%
Number of New Positive HIV Test Reports	2	1	1	2	3	2	2	5	3	3	11	13
New Positive HIV Test Reports as Proportion of All Tests Performed (%) (Test Positivity)	0.23%	0.13	0.08%	0.17%	0.23%	0.13%	0.12%	0.32%	0.49%	0.48%	0.19%	0.23%

Top of Page

Table A.2: Cumulative Number of HIV Cases and HIV Prevalence in
Canadian Federal Penitentiaries, IDSS^† 2005 – 2006.
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC
	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS)
Number of New Admissions Newly HIV-Positive	1	1	1	2	3	2	1	2	1	0	7	7
Number of New Admissions Already Known to be HIV Positive	13	7	59	64	16	17	28	36	10	31	126	155
Number of HIV Infections Amongst New Admissions	14	8	60	66	19	19	29	38	11	31	133	162
HIV Prevalence Rate Among New Admissions	2.43%	1.40%	5.65%	6.83%	1.44%	1.37%	2.15%	2.43%	2.17%	5.27%	2.76%	3.19%
Number of New HIV Diagnosis Amongst General Population Inmates	1	0	1	2	1	0	2	3	2	3	7	8
Number of Deaths of HIV-Positive Inmates	2	0	4	1	1	0	0	4	2	1	9	6
Number of HIV-Positive Inmates Released to the Community	16	10	71	64	19	23	28	39	41	57	175	193
Reported Number of HIV Positive Inmates at Year-End	15	16	53	56	40	51	45	50	51	45	204	218
Males	13	13	53	53	38	48	38	40	51	44	193	198
Females	2	3	0	3	2	3	7	10	0	1	11	20
Overall HIV prevalence	1.28%	1.24%	1.75%	1.71%	1.21%	1.42%	1.55%	1.59%	2.79%	2.28%	1.67%	1.64%
Males	1.15%	1.06%	1.79%	1.66%	1.19%	1.38%	1.37%	1.34%	2.87%	2..29%	1.63%	1.54%
Females	5.00%	5.00%	0.00%	3.66%	1.92%	2.88%	5.56%	6.85%	0.00%	1.89%	2.84%	4.49%

**Table A.3: Treatment of HIV-Positive Inmates in Canadian Federal Penitentiaries, IDSS^† 2005 - 2006.**
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC
	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS)
Total Number of Inmates Initiated on HIV Therapy	1	2	15	12	6	6	14	15	14	35	50	70
Males	0	0	13	7	6	5	10	13	14	34	43	59
Females	1	2	2	5	0	1	4	2	0	1	7	11
Average Monthly Number of HIV Positive Inmates per Month	12.6	15	64.7	61	36.9	46	41.8	46	46.8	47	203	215
Males	10.5	13	61.8	58	34.8	44	34.2	38	46.8	47	188	199
Females	2.1	3	2.8	3	2.1	2	7.7	8	0.0	1	15	16
Average Monthly Number of HIV Positive Inmates Receiving Antiretroviral Treatment	6.7	5	42.0	40	23.5	27	22.1	28	15.6	17	110	114
Males	5.9	5	40.5	38	23.5	26	18.4	22	15.6	16	104	107
Females	0.8	0	1.5	2	0.0	1	3.7	3	0.0	0	6	7
Average Monthly Proportion of Reported HIV-Positive Inmates Receiving Antiretroviral Treatment (%) (Treatment Uptake)	53.0%	32.0%	64.9%	65.5%	63.7%	59.5%	52.8%	54.4%	33.3%	35.0%	54.2%	52.9%
Males	56.3%	37.1%	65.5%	65.9%	67.5%	60.0%	53.9%	57.2%	33.3%	34.7%	55.3%	53.8%
Females	36.0%	6.7%	52.9%	59.5%	0.0%	50.0%	47.8%	41.1%	0.0%	66.7%	40.3%	41.3%

Top of Page

**Table A.4.i: HIV Screening and Testing among NEW ADMISSIONS by REGION and GENDER, Web-IDSS^† 2005 – 2006.**
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC^1a		CSC^1b
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1a – includes 41 Region unknown (38 males and 3 females); 1b - includes 16 gender unknown 2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown 3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown 4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HIV data results) 5 – total number of HIV cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested
Number of New Admissions	410	51	948	45	2,229	1	1,474	174	417	34	5,516	308	5,840
HIV History
Previous HIV Test	193	37	553	32	963	0	883	132	310	25	2,931	229	3,167
Previous HIV Test – Proportion	47.1%	72.5%	58.3%	71.1%	43.2%	0.0%	59.9%	75.9%	74.3%	73.5%	53.1%	74.4%	54.2%
Previous HIV +	3	0	4	2	19	0	9	8	5	0	40	10	50
Previous HIV + Proportion	1.6%	0.0%	0.7%	6.3%	2.0%	–	1.0%	6.1%	1.6%	0.0%	1.4%	4.4%	1.6%
Previous HIV + Treated	0	0	1	1	5	0	3	2	1	0	10	3	13
Previous HIV + Treated Proportion	0.0%	–	25.0%	50.0%	26.3%	–	33.3%	25.0%	20.0%	–	25.0%	30.0%	26.0%
HIV Screening on Admission
HIV Screening Test on Admission	402	49	916	43	1,455	1	1,339	156	332	29	4,477	281	4,770
Newly HIV Positive on Admission	2	0	1	0	0	0	4	1	2	0	9	1	10
HIV Screening Test Positivity Rate²	0.54%	0.0%	0.13%	0.0%	0.0%	–	0.42%	1.03%	0.73%	0.0%	0.30%	0.51%	0.31%
Diagnostic Yield² (newly diagnosed per 1000 tests)	5.4	0.0	1.3	0.0	0.0	–	4.2	10.3	7.3	0.0	3.0	5.1	3.1
Confirmatory Testing
Confirmed HIV Positive on Admission³	1	0	2	2	3	0	3	4	1	0	10	6	16
HIV Prevalence on Admission⁴
Total Number HIV⁵	3	0	4	2	18	0	12	9	7	0	44	11	55
HIV Prevalence – TESTED	0.81%	0.00%	0.53%	5.41%	2.98%	–	1.25%	8.91%	2.55%	0.00%	1.47%	5.47%	1.72%
HIV Prevalence – Population	0.73%	0.00%	0.42%	4.44%	0.81%	0.00%	0.81%	5.17%	1.68%	0.00%	0.80%	3.57%	0.94%

**Table A.4.ii: HIV Screening and Testing among GENERAL POPULATION by REGION and GENDER, Web-IDSS^† 2005 – 2006.**
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC^1a		CSC^1b
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1a – includes 34 Region unknown (34 males and 0 females); 1b – includes 7 gender unknown 2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown 3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown 4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HIV data results) 5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested
Number of General Population	389	24	646	12	928	2	997	97	598	39	3,592	174	3,773
HIV History
Previous HIV Test	270	18	429	3	429	0	682	56	485	22	2,321	99	2,422
Previous HIV Test – Proportion	69.4%	75.0%	66.4%	25.0%	46.2%	0.0%	68.4%	57.7%	81.1%	56.4%	64.6%	56.9%	64.2%
Previous HIV +	1	0	1	0	3	0	7	1	2	0	14	1	15
Previous HIV + Proportion	0.4%	0.0%	0.2%	0.0%	0.7%	–	1.0%	1.8%	0.4%	0.0%	0.6%	1.0%	0.6%
Previous HIV + Treated	0	0	0	0	0	0	1	0	0	0	1	0	1
Previous HIV + Treated Proportion	0.0%	–	0.0%	–	0.0%	–	14.3%	0.0%	0.0%	–	7.1%	0.0%	6.7%
HIV Screening General Population
HIV Screening Test General Population	375	24	626	12	744	1	926	92	582	36	3,286	165	3,458
Newly HIV Positive General Population	0	0	1	0	1	0	2	1	2	0	6	1	7
HIV Screening Test Positivity Rate²	0.0%	0.0%	0.20%	0.0%	0.16%	–	0.24%	1.23%	0.38%	0.0%	0.21%	0.66%	0.23%
Diagnostic Yield² (newly diagnosed per 1000 tests)	0.0	0.0	2.0	0.0	1.6	–	2.4	12.3	3.8	0.0	2.1	6.6	2.3
Confirmatory Testing
Confirmed HIV Positive General Population³	0	0	0	0	3	0	5	1	0	0	8	1	9
HIV Prevalence⁴
Total Number HIV⁵	1	0	2	0	4	0	8	2	3	0	18	2	20
HIV Prevalence – TESTED	0.30%	0.00%	0.39%	0.00%	0.64%	–	0.96%	2.44%	0.57%	0.00%	0.63%	1.31%	0.66%
HIV Prevalence – Population	0.26%	0.00%	0.31%	0.00%	0.43%	0.00%	0.80%	2.06%	0.50%	0.00%	0.50%	1.15%	0.53%

**Table A.4.iii: OVERALL HIV Prevalence by REGION and GENDER, Web-IDSS^† 2005 – 2006.**
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC^1a		CSC^1b
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1a – includes 58 Region unknown (56 males and 2 females); 1b – includes 23 gender unknown 2 – Proportion of those tested (for whom a laboratory result is recorded in Web-IDSS) who are laboratory confirmed positive 3 – Proportion of the entire population who are known to be HIV positive
Number of Inmates in Web-IDSS	748	65	1,477	50	2,863	2	2,247	224	938	59	8,329	402	8,754
HIV Testing and Results
HIV Tests	734	63	1,438	50	2,031	2	2,069	211	853	54	7,177	382	7,578
HIV Positive	3	0	4	0	17	0	17	7	8	0	49	7	56
HIV Prevalence – Tested²	0.44%	0.00%	0.33%	0.00%	1.41%	0.00%	1.01%	4.27%	1.05%	0.00%	0.88%	2.14%	0.95%
HIV Prevalence – Population³	0.40%	0.00%	0.27%	0.00%	0.59%	0.00%	0.76%	3.13%	0.85%	0.00%	0.59%	1.74%	0.64%

Top of Page

**Table A.5.i: HIV Screening and Testing among NEW ADMISSIONS by ORIGIN, Web-IDSS^† 2005 – 2006**
	Canadian-born non-Aboriginal	Canadian-born Aboriginal	Foreign-born	Unknown	CSC¹
Number of New Admissions	3,355	1,007	602	876	5,840
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 – Total number of New Admissions in Web-IDSS by Origin 2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown 3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown 4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HIV data results) 5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested
HIV History
Previous HIV Test	1,722	671	219	555	3,167
Previous HIV Test – Proportion	51.3%	66.6%	36.4%	63.4%	54.2%
Previous HIV +	25	13	4	8	50
Previous HIV + Proportion	1.5%	1.9%	1.8%	1.4%	1.6%
Previous HIV + Treated	5	4	2	2	13
Previous HIV + Treated Proportion	20.0%	30.8%	50.0%	25.0%	26.0%
HIV Screening on Admission
HIV Screening Test on Admission	2,745	881	423	721	4,770
Newly HIV Positive on Admission	4	4	0	2	10
HIV Screening Test Positivity Rate²	0.22%	0.62%	0.0%	0.41%	0.31%
Diagnostic Yield² (newly diagnosed per 1000 tests)	2.2	6.2	0.0	4.1	3.1
Confirmatory Testing
Confirmed HIV Positive on Admission³	7	5	1	3	16
HIV Prevalence on Admission⁴
Total Number HIV⁵	25	16	4	10	55
HIV Prevalence – TESTED	1.36%	2.45%	1.83%	2.04%	1.72%
HIV Prevalence – Population	0.75%	1.59%	0.66%	1.14%	0.94%

Table A.5.ii: HIV Screening and Testing among GENERAL POPULATION by
ORIGIN, Web-IDSS^† 2005 – 2006
	Canadian-born non-Aboriginal	Canadian-born Aboriginal	Foreign-born	Unknown	CSC¹
Number of general population	1,801	836	260	876	3,773
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 –total number of General Population (including temporary detainees) in Web-IDSS by Origin 2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown 3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown 4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HIV data results) 5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested
HIV History
Previous HIV Test	1,088	604	133	597	2,422
Previous HIV Test – Proportion	60.4%	72.2%	51.2%	68.2%	64.2%
Previous HIV +	6	7	0	2	15
Previous HIV + Proportion	0.6%	1.2%	0.0%	0.3%	0.6%
Previous HIV + Treated	0	1	0	0	1
Previous HIV + Treated Proportion	0.0%	14.3%	–	0.0%	6.7%
HIV Screening General Population
HIV Screening Test General Population	1,644	776	227	811	3,458
Newly HIV Positive General Population	3	1	0	3	7
HIV Screening Test Positivity Rate²	0.21%	0.15%	0.0%	0.44%	0.23%
Diagnostic Yield² (newly diagnosed per 1000 tests)	2.1	1.5	0.0	4.4	2.3
Confirmatory Testing
Confirmed HIV Positive General Population³	1	6	0	2	9
HIV Prevalence⁴
Total Number HIV⁵	8	7	0	5	20
HIV Prevalence – TESTED	0.56%	1.01%	0.00%	0.73%	0.66%
HIV Prevalence – Population	0.44%	0.84%	0.00%	0.57%	0.53%

**Table A.5.iii: OVERALL HIV Prevalence by ORIGIN, Web-IDSS^† 2005 – 2006.**
	Canadian-born non-Aboriginal	Canadian-born Aboriginal	Foreign-born	Unknown	CSC
Number of Inmates in Web-IDSS	4,679	1,652	801	1,622	8,754
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 – Proportion of those tested (for whom a laboratory result is recorded in Web-IDSS) who are laboratory confirmed positive 2 – Proportion of the entire population who are laboratory confirmed positive
HIV testing and results
HIV Tests	4,031	1,511	606	1,430	7,578
HIV Positive	26	16	3	11	56
HIV Prevalence – Tested¹	0.83%	1.27%	0.75%	0.98%	0.95%
HIV Prevalence – Population²	0.56%	0.97%	0.37%	0.68%	0.64%

Top of Page

Appendix B:
Hepatitis C Virus (HCV)

Table B.1.i: HCV Screening Antibody Tests among ALL Inmates in
Canadian Federal Penitentiaries, IDSS^† 2005-2006
Population Tested	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC
Population Tested	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS) 1 – Number of new admissions (new warrants of committal) for the calendar year. 2 – Inmate population as of January 1^st 3 – Flow through population (inmates in CSC January 1^st plus all new admissions)
New Admissions¹	576	572	1,062	966	1,322	1,389	1,351	1,564	508	588	4,819	5,079
Number of HCV Antibody Tests Performed	294	300	473	431	778	892	705	807	117	81	2,367	2,511
Proportion of All New Admissions Receiving Test (%) (Testing Uptake)	51.0%	52.4%	44.5%	44.6%	58.9%	64.2%	52.2%	51.6%	23.0%	13.8%	49.1%	49.4%
Number of New Positive HCV Test Reports	31	24	70	81	24	27	49	58	4	3	178	193
New Positive HCV Test Reports As Proportion of Tests Performed (%) (Test Positivity)	10.5%	8.0%	14.8%	18.8%	3.1%	3.0%	7.0%	7.2%	3.4%	3.7%	7.5%	7.7%
General Population²	1,168	1,292	3,033	3,283	3,295	3,592	2,900	3,139	1,826	1,974	12,222	13,280
Number of Tests Performed	528	429	721	646	592	651	908	826	373	446	3,122	2,998
Proportion of All General Population Inmates Receiving Test (%) (Testing Uptake)	45.2%	33.2%	23.8%	19.7%	18.0%	18.1%	31.3%	26.3%	20.4%	22.6%	25.5%	22.6%
Number of New Positive HCV Test Reports	48	52	15	22	31	33	52	33	30	24	176	164
New Positive HCV Test Reports as Proportion of Tests Performed (%) (Test Positivity)	9.1%	12.1%	2.1%	3.4%	5.2%	5.1%	5.7%	4.0%	8.0%	5.4%	5.6%	5.5%
Total³	1,744	1,864	4,095	4,249	4,617	4,981	4,251	4,703	2,334	2,562	17,041	18,359
Number of Tests Performed	822	729	1,194	1,077	1,370	1,543	1,613	1,633	490	527	5,489	5,509
Proportion of Inmates Receiving Test (%) (Testing Uptake)	47.1%	31.9%	29.2%	25.3%	29.7%	31.0%	37.9%	34.7%	21.0%	20.6%	32.2%	30.0%
Number of New Positive HCV Test Reports	79	76	85	103	55	60	101	91	34	27	354	357
New Positive HCV Test Reports as Proportion of All Tests Performed (%) (Test Positivity)	9.6%	10.4%	7.1%	9.6%	4.0%	3.9%	6.3%	5.6%	7.0%	5.1%	6.5%	6.5%

Table B.1:ii HCV Screening Antibody Tests among FEMALE Inmates in
Canadian Federal Penitentiaries, IDSS^† 2005-2006
Population Tested	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC
Population Tested	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS) 1 – Number of female new admissions (new warrants of committal) for the calendar year. 2 – Female Inmate population as of January 1^st 3 – Flow through population (inmates in CSC January 1^st plus all new admissions).
New Admissions¹	42	39	35	39	74	90	99	95	20	40	270	303
Number of HCV Antibody Tests Performed	23	23	31	37	116	98	79	121	2	15	251	294
Proportion of All New Admissions Receiving Test (%) (Testing Uptake)	54.8%	59.0%	88.6%	94.9%	157%	109%	79.8%	127%	10.0%	37.5%	93.0%	97.0%
Number of New Positive HCV Test Reports	6	2	4	4	3	1	5	0	1	0	19	7
New Positive HCV Test Reports as Proportion of Tests Performed (%) (Test Positivity)	26.1%	8.7%	12.9%	10.8%	2.6%	1.0%	6.3%	0.0%	50.0%	0.0%	7.6%	2.4%
General Population²	40	60	70	82	104	104	126	146	47	53	387	445
Number of Tests Performed	19	33	9	3	7	15	44	50	14	14	93	115
Proportion of All General Population Inmates Receiving Test (%)(Testing Uptake)	47.5%	55.0%	12.9%	3.7%	6.7%	14.4%	34.9%	34.2%	29.8%	26.4%	24.0%	25.8%
Number of New Positive HCV Test Reports	0	3	0	0	0	0	2	0	2	0	4	3
New Positive HCV Test Reports as Proportion of Tests Performed (%) (Test Positivity)	0.0%	9.1%	0.0%	0.0%	0.0%	0.0%	4.6%	0.0%	14.3%	0.0%	4.3%	2.6%
Total³	82	99	105	121	178	194	225	241	67	93	657	748
Number of Tests Performed	42	56	40	40	123	113	123	171	16	29	344	409
Proportion of Inmates Receiving Test (%) (Testing Uptake)	51.2%	56.6%	38.1%	33.1%	69.1%	58.2%	54.7%	71%	23.9%	31.2%	52.4%	54.7%
Number of New Positive HCV Test Reports	6	5	4	4	3	1	7	0	3	0	23	10
New Positive HCV Test Reports as Proportion of All Tests Performed (%) (Test Positivity)	14.3%	8.9%	10.0%	10.0%	2.4%	0.9%	5.7%	0.0%	18.6%	0.0%	6.7%	2.4%

Top of Page

Table B.1.iii: HCV Screening Antibody Tests among MALE Inmates in
Canadian Federal Penitentiaries, IDSS^† 2005-2006
Population Tested	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC
Population Tested	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS) 1 – Number of male new admissions (new warrants of committal) for the calendar year. 2 – Male Inmate population as of January 1^st 3 – Flow through population (inmates in CSC January 1^st plus all new admissions)
New admissions¹	534	533	1,027	927	1,248	1,299	1,252	1,469	488	548	4,549	4,776
Number of HCV Antibody Tests Performed	271	277	442	394	662	794	626	686	115	66	2,116	2,217
Proportion of All New Admissions Receiving Test (%) (Testing Uptake)	50.7%	52.0%	43.0%	42.5%	53.0%	61.1%	50.0%	46.7%	23.6%	12.0%	46.5%	46.4%
Number of New Positive HCV Test Reports	25	22	66	77	21	26	44	58	3	3	159	186
New Positive HCV Test Reports as Proportion of Tests Performed (%) (Test Positivity)	9.2%	7.9%	14.9%	19.5%	3.2%	3.3%	7.0%	8.5%	2.6%	4.6%	7.5%	8.4%
General Population²	1,128	1,232	2,963	3,201	3,191	3,488	2,774	2,993	1,779	1,921	11,835	12,835
Number of Tests Performed	509	396	712	643	585	636	864	776	359	432	3,029	2,883
Proportion of All General Population Inmates Receiving Test (%) (Testing Uptake)	45.1%	32.1%	24.0%	20.10%	18.3%	18.2%	31.1%	25.9%	20.2%	22.5%	25.6%	22.5%
Number of New Positive HCV Test Reports	48	49	15	22	31	33	50	33	28	24	172	161
New Positive HCV Test Reports as Proportion of Tests Performed (%) (Test Positivity)	9.4%	12.4%	2.1%	3.4%	5.3%	5.2%	5.8%	4.3%	7.8%	5.6%	5.7%	5.6%
Total³	1,662	1,765	3,990	4,128	4,439	4,787	4,026	4,462	2,267	2,469	16,384	17,611
Number of Tests Performed	780	673	1,154	1,037	1,247	1,430	1,490	1,462	474	498	5,145	5,100
Proportion of Inmates Receiving Test (%) (Testing Uptake)	46.9%	38.1%	28.9%	25.1%	28.1%	29.9%	37.0%	32.8%	20.9%	20.2%	31.4%	29.0%
Number of New Positive HCV Test Reports	73	71	81	99	52	59	94	91	31	27	331	347
New Positive HCV Test Reports as Proportion of All Tests Performed (%) (Test Positivity)	9.4%	10.6%	7.0%	9.6%	4.2%	4.1%	6.3%	6.2%	6.5%	5.4%	6.4%	6.8%

Table B.2: Cumulative Number of HCV Cases and HCV Prevalence in
Canadian Federal Penitentiaries, IDSS^† 2005 – 2006.
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC
Population Tested	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS)
Number of New Admissions Newly HCV-Positive	31	24	70	81	24	27	49	58	4	3	178	193
Number of New Admissions Already Known to be HCV Positive	154	120	276	350	167	209	344	374	93	112	1,034	1,165
Number of HCV Infections Amongst New Admissions	185	144	346	431	191	236	393	432	97	115	1,212	1,358
HCV Prevalence Rate Among New Admissions	32.1%	25.2%	32.6%	44.6%	14.5%	17.0%	29.1%	27.6%	19.1%	19.6%	25.2%	26.7%
Number of New HCV Diagnosis Amongst General Population Inmates	48	52	15	22	31	33	52	33	30	24	176	164
Number of Deaths of HCV-Positive Inmates	1	0	6	1	2	3	2	5	7	3	18	12
Number of HCV-Positive Inmates Released to the Community	220	215	371	381	471	470	556	568	447	549	2,065	2,183
Reported Number of HCV Positive Inmates at Year-End.	361	450	542	634	970	924	886	878	822	775	3,581	3,661
Males	338	422	522	616	939	892	839	821	790	750	3,428	3,501
Females	23	28	20	18	31	32	47	57	32	25	153	160
Overall HCV Prevalence	30.9%	34.8%	17.9%	19.3%	29.4%	25.7%	30.6%	28.0%	45.0%	39.3%	29.3%	27.6%
Males	30.0%	34.3%	17.6%	19.2%	29.4%	25.6%	30.2%	27.4%	44.4%	37.0%	29.0%	27.3%
Females	57.5%	46.7%	28.6%	22.0%	29.8%	30.8%	37.3%	39.0%	68.1%	47.2%	39.5%	36.0%

Table B.3: Treatment of HCV-Positive Inmates in
Canadian Federal Penitentiaries, IDSS^† 2005 - 2006.
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC
	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS)
Total Number of Inmates Initiated on HCV Therapy	11	21	72	83	34	78	56	56	94	132	267	370
Males	11	16	64	75	34	70	53	52	89	122	251	335
Females	0	5	8	8	0	8	3	4	5	10	16	35
Average Monthly Number of HCV Positive Inmates per Month	342	413	561.6	588	950.5	943	864.4	862	853.1	816	3,572	3,621
Males	323	387	538.4	571	917.7	911	811.3	811	828.6	787	3,419	3,468
Females	20	25	23.2	17	32.8	32	53.1	51	24.5	29	153	154
Average Monthly Number of HCV Positive Inmates Receiving Antiviral Treatment	6.9	8	36.9	48	14.2	35	22.4	27	55.6	66	136	184
Males	6.0	6	34.8	44	13.4	30	20.8	27	52.1	62	127	169
Females	0.9	1	2.2	4	0.8	5	1.7	1	3.5	4	9	15

Top of Page

**Table B.4.i: HCV Screening and Testing among NEW ADMISSIONS by REGION and GENDER, Web-IDSS^† 2005 – 2006.**
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC^1a		CSC^1b
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1a – includes 41 Region unknown (38 males and 3 females); 1b - includes 16 gender unknown 2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown 3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown 4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HCV data results) 5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested
Number of New Admissions	410	51	948	45	2,229	1	1,474	174	417	34	5,516	308	5,840
HCV History
Previous HCV Test	180	35	498	29	905	0	785	110	278	22	2,675	199	2,880
Previous HCV Test – Proportion	43.9%	68.6%	52.5%	64.4%	40.6%	0.0%	53.3%	63.2%	66.7%	64.7%	48.5%	64.6%	49.3%
Previous HCV +	33	12	109	9	218	0	196	54	110	10	673	88	761
Previous HCV + Proportion	18.3%	34.3%	21.9%	31.0%	24.1%	–	25.0%	49.1%	39.6%	45.5%	25.2%	44.2%	26.4%
Previous HCV + Treated	2	1	27	3	12	0	13	2	14	0	69	6	75
Previous HCV + Treated Proportion	6.1%	8.3%	24.8%	33.3%	5.5%	–	6.6%	3.7%	12.7%	0.0%	10.3%	6.8%	9.9%
HCV Screening on Admission
HCV Screening Test on Admission	365	38	793	33	1,324	1	1,149	114	248	19	3,904	205	4,121
Newly HCV Positive on Admission	19	5	35	0	46	0	75	11	30	0	207	16	224
HCV Screening Test Positivity Rate²	6.1%	17.9%	5.9%	0.0%	9.3%	–	10.0%	16.7%	16.5%	0.0%	8.8%	12.7%	9.0%
Diagnostic Yield² (newly diagnosed per 1000 tests)	61	179	59	0	93	–	100	167	165	0	88	127	90
Confirmatory Testing
Confirmed HCV Positive on Admission³	7	9	41	7	51	0	53	20	14	2	169	39	208
HCV Prevalence On Admission⁴
Total Number HCV⁵	48	17	143	9	259	0	264	64	138	10	858	103	962
HCV Prevalence – TESTED	14.8%	45.9%	22.4%	30.0%	46.8%	–	32.5%	73.6%	69.7%	90.9%	33.6%	62.0%	35.3%
HCV Prevalence – Population	11.7%	33.3%	15.1%	20.0%	11.6%	0.0%	17.9%	36.8%	33.1%	29.4%	15.6%	33.4%	16.5%

**Table B.4.ii: HCV Screening and Testing among GENERAL POPULATION by REGION and GENDER, Web-IDSS^† 2005 – 2006.**
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC^1a		CSC^1b
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1a – includes 34 Region unknown (34 males and 0 females); 1b – includes 7 gender unknown 2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown 3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown 4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HCV data results) 5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested
Number of General Population	389	24	646	12	928	2	997	97	598	39	3,592	174	3,773
HCV History
Previous HCV Test	258	18	397	3	399	0	638	54	462	19	2,179	94	2,276
Previous HCV Test – Proportion	66.3%	75.0%	61.5%	25.0%	43.0%	0.0%	64.0%	55.7%	77.3%	48.7%	60.7%	54.0%	60.3%
Previous HCV +	45	5	95	1	82	0	175	23	154	11	555	40	596
Previous HCV + Proportion	17.4%	27.8%	23.9%	33.3%	20.6%	–	27.4%	42.6%	33.3%	57.9%	25.5%	42.6%	26.2%
Previous HCV + Treated	3	0	20	1	5	0	17	1	37	1	83	3	86
Previous HCV + Treated Proportion	6.7%	0.0%	21.1%	100.0%	6.1%	–	9.7%	4.3%	24.0%	9.1%	15.0%	7.5%	14.4%
HCV Screening General Population
HCV Screening Test General Population	335	17	519	10	688	1	744	67	406	28	2,721	123	2,850
Newly HCV Positive General Population	35	4	36	2	103	0	77	11	52	8	308	25	334
HCV Screening Test Positivity Rate²	12.3%	25.0%	9.5%	20.0%	18.7%	0.0%	12.6%	19.6%	15.6%	38.1%	14.1%	24.0%	14.6%
Diagnostic Yield² (newly diagnosed per 1000 tests)	123	250	95	200	187	0	126	196	156	381	141	240	146
Confirmatory Testing
Confirmed HCV Positive General Population³	12	2	18	0	9	0	43	13	27	4	110	19	130
HCV Prevalence⁴
Total Number HCV⁵	81	8	127	3	185	0	249	36	201	20	851	67	920
HCV Prevalence – TESTED	27.5%	42.1%	31.7%	30.0%	33.0%	0.0%	38.0%	53.7%	55.1%	87.0%	37.0%	55.8%	37.9%
HCV Prevalence – Population	20.8%	33.3%	19.7%	25.0%	19.9%	0.0%	25.0%	37.1%	33.6%	51.3%	23.7%	38.5%	24.4%

**Table B.4.iii: OVERALL HCV Prevalence by REGION and GENDER, Web-IDSS^† 2005 – 2006.**
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC^1a		CSC^1b
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1a – includes 58 Region unknown (56 males and 2 females); 1b – includes 23 gender unknown 2 – Proportion of those tested (for whom a laboratory result is recorded in Web-IDSS) who are laboratory confirmed positive 3 – Proportion of the entire population who are laboratory confirmed positive
Number of Inmates in Web-IDSS	748	65	1,477	50	2,863	2	2,247	224	938	59	8,329	402	8,754
HCV Testing and Results
HCV Tests	696	61	1,346	47	1,977	2	1,915	205	708	49	6,690	366	7,075
HCV Positive	113	16	228	5	360	0	437	64	310	25	1,458	111	1,572
HCV Prevalence – Tested²	18.9%	30.2%	22.7%	12.5%	32.8%	0.0%	31.1%	44.8%	56.7%	71.4%	31.1%	40.7%	31.6%
HCV Prevalence – Population³	15.1%	24.6%	15.4%	10.0%	12.6%	0.0%	19.4%	28.6%	33.0%	42.4%	17.5%	27.6%	18.0%

**Table B.5.i: HCV Screening and Testing among NEW ADMISSIONS by ORIGIN, Web-IDSS^† 2005 – 2006**
	Canadian-born non-Aboriginal	Canadian-born Aboriginal	Foreign-born	Unknown	CSC¹
Number of New Admissions	3,355	1,007	602	876	5,840
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 –total number of New Admissions in Web-IDSS by Origin 2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown 3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown 4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HCV data results) 5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested
HCV History
Previous HCV Test	1,564	607	185	524	2,880
Previous HCV Test – Proportion	46.6%	60.3%	30.7%	59.8%	49.3%
Previous HCV +	387	196	11	167	761
Previous HCV + Proportion	24.7%	32.3%	5.9%	31.9%	26.4%
Previous HCV + Treated	37	16	0	22	75
Previous HCV + Treated Proportion	9.6%	8.2%	0.0%	13.2%	9.9%
HCV Screening on Admission
HCV Screening Test on Admission	2,408	726	420	567	4,121
Newly HCV Positive on Admission	116	62	4	42	224
HCV Screening Test Positivity Rate²	7.9%	13.1%	2.0%	12.1%	9.0%
Diagnostic Yield² (newly diagnosed per 1000 tests)	79	131	20	121	90
Confirmatory Testing
Confirmed HCV Positive on Admission³	117	58	1	32	208
HCV Prevalence On Admission⁴
Total Number HCV⁵	489	250	15	208	962
HCV Prevalence – TESTED	30.5%	46.3%	7.4%	54.6%	35.3%
HCV Prevalence – Population	14.6%	24.8%	2.5%	23.7%	16.5%

Top of Page

Table B.5.ii: HCV Screening and Testing among GENERAL POPULATION by ORIGIN,
Web-IDSS^† 2005 – 2006
	Canadian-born Non-Aboriginal	Canadian-born Aboriginal	Foreign-born	Unknown	CSC¹
Number of General Population	1,801	836	260	876	3,773
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 –total number of General Population (including temporary detainees) in Web-IDSS by Origin 2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown 3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown 4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission ((see section on Enhanced HCV data results) 5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested
HCV History
Previous HCV Test	1,024	567	118	567	2,276
Previous HCV Test – Proportion	56.9%	67.8%	45.4%	64.7%	60.3%
Previous HCV +	245	176	10	165	596
Previous HCV + Proportion	23.9%	31.0%	8.5%	29.1%	26.2%
Previous HCV + Treated	33	23	3	27	86
Previous HCV + Treated Proportion	13.5%	13.1%	30.0%	16.4%	14.4%
HCV Screening General Population
HCV Screening Test General Population	1,405	608	212	625	2,850
Newly HCV Positive General Population	162	77	8	87	334
HCV Screening Test Positivity Rate²	14.3%	15.6%	4.4%	18.0%	14.6%
Diagnostic Yield² (newly diagnosed per 1000 tests)	143	156	44	180	146
Confirmatory Testing
Confirmed HCV Positive General Population³	43	52	2	33	130
HCV Prevalence⁴
Total Number HCV⁵	402	251	18	249	920
HCV Prevalence – TESTED	34.0%	46.1%	9.9%	48.2%	37.9%
HCV Prevalence – Population	22.3%	30.0%	6.9%	28.4%	24.4%

**Table B.5.iii: OVERALL HCV Prevalence by ORIGIN, Web-IDSS^† 2005 – 2006.**
	Canadian-born Non-Aboriginal	Canadian-born Aboriginal	Foreign-born	Unknown	CSC
Number of Inmates in Web-IDSS	4,679	1,652	801	1,622	8,754
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 – Proportion of those tested (for whom a laboratory result is recorded in Web-IDSS) who are laboratory confirmed positive 2 – Proportion of the entire population who are laboratory confirmed positive
HCV Testing and Results
HCV Tests	3,817	1,394	599	1,265	7,075
HCV Positive	736	409	29	398	1,572
HCV Prevalence – Tested¹	27.4%	39.4%	7.7%	45.8%	31.6%
HCV Prevalence – Population²	15.7%	24.8%	3.6%	24.5%	18.0%

Top of Page

Appendix C:
Hepatitis A (HAV) and Hepatitis B (HBV) Virus

**Table C.1: Hepatitis A and B Cases by REGION and GENDER, IDSS^†, 2005 - 2006.**
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC
	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS)
Hepatitis A (HAV)
Acute HAV Cases (Women)	0	0	0	0	0	1	0	0	0	0	0	1
AcuteHAV Cases (Men)	0	0	0	0	0	0	0	0	0	0	0	0
Total Number of Acute HAV Cases	0	0	0	0	0	1	0	0	0	0	0	1
Acute HAV Case Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%
Hepatitis B (HBV)
Acute HBV Cases (Women)	0	0	1	0	0	0	0	0	0	0	1	0
Acute HBV Cases (Men)	0	1	3	5	2	0	0	2	0	1	5	9
Total Number of Acute HBV Cases	0	1	4	5	2	0	0	2	0	1	6	9
Acute HBV Case Rate	0.00%	0.08%	0.13%	0.15%	0.06%	0.00%	0.00%	0.06%	0.00%	0.05%	0.05%	0.07%

Table C.2.i: HAV Testing and Vaccination History, HAV Testing and Serology among
NEW ADMISSIONS by REGION and GENDER, Web-IDSS^† 2005 – 2006.
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC^1a		CSC^1b
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS). 1a – includes 41 Region unknown (38 males and 3 females); 1b – includes 16 gender unknown 2 – Self-reported vaccination history 3 – Reactive for anti-HAV IgM, HAV IgG or total anti-HAV.
Number of New Admissions	410	51	948	45	2,229	1	1,474	174	417	34	5,516	308	5,840
Testing and HAV Vaccination History (Self Report)
Previous HAV Test	104	10	196	23	840	0	477	68	138	18	1,766	122	1,892
Previous HAV Test Rate	25.4%	19.6%	20.7%	51.1%	37.7%	0.0%	32.4%	39.1%	33.1%	52.9%	32.0%	39.6%	32.4%
Previous HAV Positive	4	0	8	0	16	0	17	10	11	1	56	11	68
Previous HAV Positive Rate	3.8%	0.0%	4.1%	0.0%	1.9%	–	3.6%	14.7%	8.0%	5.6%	3.2%	9.0%	3.6%
Previous HAV Positive Treatment	0	0	1	0	0	0	2	1	3	1	6	2	8
Previous HAV Positive Treatment Rate	0.0%	–	12.5%	–	0.0%	–	11.8%	10.0%	27.3%	100.0%	10.7%	18.2%	11.8%
HAV Vaccination History²	139	7	452	21	182	0	306	42	173	16	1,269	89	1,359
HAV Vaccination History Rate	33.9%	13.7%	47.7%	46.7%	8.2%	0.0%	20.8%	24.1%	41.5%	47.1%	23.0%	28.9%	23.3%
HAV Testing and Serology among new admissions
HAV Serological Tests	115	15	190	37	1,446	1	1,040	144	122	11	2,926	210	3,143
HAV Serological Tests Rate	28.0%	29.4%	20.0%	82.2%	64.9%	100.0%	70.6%	82.8%	29.3%	32.4%	53.0%	68.2%	53.8%
Number with Serological Immunity³	21	2	26	4	177	0	136	25	26	3	388	35	425
HAV Test Positivity	30.9%	25.0%	41.3%	30.8%	29.5%	–	27.2%	32.9%	34.7%	100.0%	29.5%	34.7%	29.9%

Table C.2.ii: HAV Testing and Vaccination History, HAV Testing and Serology among GENERAL POPULATION by
RE GION and GENDER, Web-IDSS^† 2005 – 2006.
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC^1a		CSC^1b
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS). 1a – includes 34 Region unknown (34 males and 0 females); 1b – includes 7 gender unknown 2 – Self-reported vaccination history 3 – Reactive for anti-HAV IgM, HAV IgG, or total anti-HAV.
Number of General Population	389	24	646	12	928	2	997	97	598	39	3,592	174	3,773
Testing and HAV Vaccination History
Previous HAV Test	112	8	167	0	274	0	397	32	194	9	1,163	49	1,213
Previous HAV Test Rate	28.8%	33.3%	25.9%	0.0%	29.5%	0.0%	39.8%	33.0%	32.4%	23.1%	32.4%	28.2%	32.1%
Previous HAV Positive	25	0	4	0	12	0	25	7	16	0	84	7	92
Previous HAV Positive Rate	22.3%	0.0%	2.4%	–	4.4%	–	6.3%	21.9%	8.2%	0.0%	7.2%	14.3%	7.6%
Previous HAV Positive Treatment	3	0	1	0	1	0	0	1	3	0	9	1	10
Previous HAV Positive Treatment Rate	12.0%	–	25.0%	–	8.3%	–	0.0%	14.3%	18.8%	–	10.7%	14.3%	10.9%
HAV Vaccination History²	168	4	314	2	134	0	418	21	296	13	1,344	40	1,386
HAV Vaccination History Rate	41.0%	16.7%	48.6%	16.7%	14.4%	0.0%	41.9%	21.6%	49.5%	33.3%	37.4%	23.0%	36.7%
HAV Testing and Serology among general population
HAV Serological Tests	265	6	229	6	624	1	446	52	153	16	1,731	81	1,818
HAV Serological Tests Rate	68.1%	25.0%	35.4%	50.0%	67.2%	50.0%	44.7%	53.6%	25.6%	41.0%	48.2%	46.6%	48.2%
Number with Serological Immunity³	128	1	36	0	171	0	88	9	34	9	459	19	481
HAV Test Positivity	62.1%	16.7%	39.6%	0.0%	36.6%	0.0%	33.6%	28.1%	45.9%	60.0%	41.6%	32.2%	41.2%

**Table C.2.iii: HAV Testing and Vaccination History, HAV Testing and Serology among NEW ADMISSIONS by ORIGIN, Web-IDSS^† 2005 – 2006.**
	Canadian-born	Aboriginal	Foreign-born	Unknown	CSC¹
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS). 1 – Total number of new admissions by Origin (including Unknown) in enhanced surveillance. 2 – Self-reported vaccination history 3 – Reactive for anti-HAV IgM, HAV IgG, or total anti-HAV.
Number of New Admissions	3,355	1,007	602	876	5,840
Testing and HAV Vaccination History (Self Report)
Previous HAV Test	1,030	393	149	320	1,892
Previous HAV Test Rate	30.7%	39.0%	24.8%	36.5%	32.4%
Previous HAV Positive	32	21	5	10	68
Previous HAV Positive Rate	3.1%	5.3%	3.4%	3.1%	3.6%
Previous HAV Positive Treatment	3	3	0	2	8
Previous HAV Positive Treatment Rate	9.4%	14.3%	0.0%	20.0%	11.8%
HAV Vaccination History²	781	279	70	229	1,359
HAV Vaccination History Rate	23.3%	27.7%	11.6%	26.1%	23.3%
HAV Testing and Serology on Admission
HAV Serological Tests	1,721	644	335	443	3,143
HAV Serological Tests Rate	51.3%	64.0%	55.6%	50.6%	53.8%
Number with Serological Immunity³	166	125	71	63	425
HAV Test Positivity	22.0%	38.3%	53.8%	30.4%	29.9%

Top of Page

Table C.2.iv: HAV Testing and Vaccination History, HAV Testing and Serology among
GENERAL POPULATION by ORIGIN, Web-IDSS^† 2005 – 2006.
	Canadian-born	Aboriginal	Foreign-born	Unknown	CSC¹
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS). 1 – Total number of new admissions by Origin (including Unknown) in enhanced surveillance. 2 – Web-IDSS did not have a results record for each test requisition. 3 – Reactive for anti-HAV IgM, HAV IgG, or total anti-HAV.
Number of General Population	1,801	836	260	876	3,773
Testing and HAV Vaccination History (Self Report)
Previous HAV Test	514	335	76	288	1,213
Previous HAV Test Rate	28.5%	40.1%	29.2%	32.9%	32.1%
Previous HAV Positive	32	27	10	23	92
Previous HAV Positive Rate	6.2%	8.1%	13.2%	8.0%	7.6%
Previous HAV Positive Treatment	7	2	0	1	10
Previous HAV Positive Treatment Rate	21.9%	7.4%	0.0%	4.3%	10.9%
HAV Vaccination History	661	346	66	313	1,386
HAV Vaccination History Rate	19.7%	41.4%	25.4%	35.7%	36.7%
HAV Testing and Serology as General Population
HAV Serological Tests	898	354	146	420	1,818
HAV Serological Tests Rate	49.9%	42.3%	56.2%	47.9%	48.2%
Number with Serological Immunity³	209	89	63	120	481
HAV Test Positivity	35.4%	43.8%	64.3%	43.5%	41.2%

Table C.3.i: HBV Testing and Vaccination History, HBV Testing and Serology among
NEW ADMISSIONS by REGION and GENDER, Web-IDSS^† 2005 – 2006.
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC^1a		CSC^1b
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS). 1a – includes 41 Region unknown (38 males and 3 females); 1b – includes 16 gender unknown 2 – Self-reported vaccination history 3 –Reactive for total anti-HBc, anti-HBc IgM, anti-HBe, anti-HBs, HBeAg or HBsAg.
Number of New Admissions	410	51	948	45	2,229	1	1,474	174	417	34	5,516	308	5,840
Testing and HBV Vaccination History (Self Report)
Previous HBV Test	115	32	456	28	859	0	528	74	160	20	2,129	157	2,290
Previous HBV Test Rate	28.0%	62.7%	48.1%	62.2%	38.5%	0.0%	35.8%	42.5%	38.4%	58.8%	38.6%	51.0%	39.2%
Previous HBV Positive	5	1	20	0	30	0	22	12	20	0	98	13	112
Previous HBV Positive Rate	4.3%	3.1%	4.4%	0.0%	3.5%	–	4.2%	16.2%	12.5%	0.0%	4.6%	8.3%	4.9%
Previous HBV Positive Treatment	0	0	7	0	1	0	1	1	1	0	10	1	11
Previous HBV Positive Treatment Rate	0.0%	0.0%	35.0%	–	3.3%	–	4.5%	8.3%	5.0%	–	10.2%	7.7%	9.8%
HBV Vaccination History²	165	20	572	23	314	0	459	55	196	21	1,725	122	1,850
HBV Vaccination History Rate	40.2%	39.2%	60.3%	51.1%	14.1%	0.0%	31.1%	31.6%	47.0%	61.8%	31.3%	39.6%	31.7%
HBV Testing and Serology on Admission
HBV Serological Tests	123	48	824	40	1,429	1	1,096	141	127	13	3,619	245	3,873
HBV Serological Tests Rate	30.0%	94.1%	86.9%	88.9%	64.1%	100.0%	74.4%	81.0%	30.5%	38.2%	65.6%	79.5%	66.3%
Number with Serological Immunity³	14	6	373	17	248	0	174	24	38	2	852	50	904
HBV Test Positivity	15.6%	15.8%	54.5%	53.1%	40.5%	–	26.9%	29.3%	49.4%	28.6%	40.1%	31.1%	39.4%

Table C.3.ii: HBV Testing and Vaccination History, HBV Testing and Serology among
GENERAL POPULATION by REGION and GENDER, Web-IDSS^† 2005 – 2006.
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC^1a		CSC^1b
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS). 1a – includes 34 Region unknown (34 males and 0 females); 1b – includes 7 gender unknown 2 – Self-reported vaccination history 3 – Reactive for total anti-HBc, anti-HBc IgM, anti-HBe, anti-HBs, HBeAg or HBsAg.
Number of General Population	389	24	646	12	928	2	997	97	598	39	3,592	174	3,773
Testing and HBV Vaccination History
Previous HBV Test	129	18	301	1	284	0	481	36	191	9	1,405	64	1,471
Previous HBV Test Rate	33.2%	75.0%	46.6%	8.3%	30.6%	0.0%	48.2%	37.1%	31.9%	23.1%	39.1%	36.8%	39.0%
Previous HBV Positive	35	0	16	0	16	0	21	9	18	0	109	9	118
Previous HBV Positive Rate	27.1%	0.0%	5.3%	0.0%	5.6%	–	4.4%	25.0%	9.4%	0.0%	7.8%	14.1%	8.0%
Previous HBV Positive Treatment	2	0	2	0	3	0	0	1	7	0	15	1	16
Previous HBV Positive Treatment Rate	5.7%	–	12.5%	–	18.8%	–	0.0%	11.1%	38.9%	–	13.8%	11.1%	13.6%
HBV Vaccination History	258	14	386	3	190	0	502	33	338	15	1,696	65	1,764
HBV Vaccination History Rate	66.3%	58.3%	59.8%	25.0%	20.5%	0.0%	50.4%	34.0%	56.5%	38.5%	47.2%	37.4%	46.8%
HAV Testing and Serology on General Population
HBV Serological Tests	260	23	381	10	593	1	533	52	152	19	1,941	105	2,053
HBV Serological Tests Rate	66.8%	95.8%	59.0%	83.3%	63.9%	50.0%	53.5%	53.6%	25.4%	48.7%	54.0%	60.3%	54.4%
Number with Serological Immunity³	157	6	183	6	217	0	124	13	36	12	728	37	767
HBV Test Positivity	71.0%	33.3%	59.6%	60.0%	44.9%	0.0%	31.8%	36.1%	42.9%	70.6%	48.6%	45.1%	48.3%

Top of Page

Table C.3.iii: HBV Testing and Vaccination History, HBV Testing and Serology among
NEW ADMISSIONS by ORIGIN, Web-IDSS^† 2005 – 2006.
	Canadian-born	Aboriginal	Foreign-born	Unknown	CSC¹
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS). 1 – Total number of new admissions by Origin (including Unknown) in enhanced surveillance. 2 – Self-reported vaccination history 3 – Reactive for total anti-HBc, anti-HBc IgM, anti-HBe, anti-HBs, HBeAg or HBsAg.
Number of New Admissions	3,355	1,007	602	876	5,840
Testing and Vaccination History (Self Report)
Previous HBV Test	1,287	434	168	401	2,290
Previous HBV Test Rate	38.4%	43.1%	27.9%	45.8%	39.2%
Previous HBV Positive	55	27	9	21	112
Previous HBV Positive Rate	4.3%	6.2%	5.4%	5.2%	4.9%
Previous HBV Positive Treatment	4	1	2	4	11
Previous HBV Positive Treatment Rate	7.3%	3.7%	22.2%	19.0%	9.8%
HBV Vaccination History²	1,039	367	90	354	1,850
HBV Vaccination History Rate	31.0%	36.4%	15.0%	40.4%	31.7%
HBV Testing and Serology on Admission
HBV Serological Tests	2,256	700	390	527	3,873
HBV Serological Tests Rate	67.2%	69.5%	64.8%	60.2%	66.3%
Number with Serological Immunity³	544	149	82	129	904
HBV Test Positivity	40.1%	33.5%	42.7%	43.1%	39.4%

Table C.3.iv: HBV Testing and Vaccination History, HBV Testing and Serology among
GENERAL POPULATION by ORIGIN, Web-IDSS^† 2005 – 2006.
	Canadian-born	Aboriginal	Foreign-born	Unknown	CSC¹
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS). 1 – Total number of new admissions by Origin (including Unknown) in enhanced surveillance. 2 – Web-IDSS did not have a results record for each test requisition. 3 – Reactive for total anti-HBc, anti-HBc IgM, anti-HBe, anti-HBs, HBeAg or HBsAg.
Number of General Population	1,801	836	260	876	3,773
Testing and Vaccination History (Self Report)
Previous HBV Test	641	375	84	371	1,471
Previous HBV Test Rate	35.6%	44.9%	32.3%	42.4%	39.0%
Previous HBV Positive	48	25	6	39	118
Previous HBV Positive Rate	7.5%	6.7%	7.1%	10.5%	8.0%
Previous HBV Positive Treatment	8	3	0	5	16
Previous HBV Positive Treatment Rate	16.7%	12.0%	0.0%	12.8%	13.6%
HBV Vaccination History²	831	416	82	435	1,764
HBV Vaccination History Rate	46.1%	49.8%	31.5%	49.7%	46.8%
HBV Testing and Serology as General Population
HBV Serological Tests	1,038	402	156	457	2,053
HBV Serological Tests Rate	57.6%	48.1%	60.0%	52.2%	54.4%
Number with Serological Immunity³	408	115	64	180	767
HBV Test Positivity	49.6%	39.5%	51.6%	51.4%	48.3%

Table C.4.i: Infectious HAV and HBV Cases and HBV Carriers by
REGION and GENDER, Web-IDSS^† 2005 – 2006.
	Atlantic	Quebec	Ontario	Prairie	Pacific	CSC
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS). 1 – Based on reactive serology result for anti-HAV IgM; 2 – Includes one HAV case Region unknown; 3 – Based on reactive serology result for anti-HBc IgM; 4 – Based on reactive serology result for anti-HBc IgM or HBsAg; 5 – Includes 2 Region unknown ( males=2 and females=0).
Acute (Active) HAV Cases¹
Acute HAV Cases among New Admissions	1	2	0	7	2	12
Acute HAV cases (Men)	0	1	0	7	2	10
Acute HAV cases (Women)	1	1	0	0	0	2
Acute HAV Cases among General Population²	2	1	1	2	4	11
Acute HAV cases (Men)	2	1	1	2	4	10
Acute HAV cases (Women)	0	0	0	0	0	0
Total number of Acute HAV cases	3	3	1	9	6	23
Acute HBV Cases (Active Case)³
Acute HBV Cases among New Admissions	0	3	3	0	5	11
Acute HBV cases (Men)	0	3	3	0	5	11
Acute HBV cases (Women)	0	0	0	0	0	0
Acute HBV Cases among General Population	0	5	6	1	2	14
Acute HBV cases (Men)	0	5	6	1	2	14
Acute HBV cases (Women)	0	0	0	0	0	0
Total number of Acute HBV cases	0	8	9	1	7	25
All Infectious HBV Carriers (Cases)⁴
Acute HBV Carriers among New Admissions	1	7	10	12	16	46
HBV carriers (Men)	1	7	10	6	16	40
HBV carriers (Women)	0	0	0	6	0	6
Acute HBV Carriers among General Population⁵	7	8	16	17	4	54
HBV carriers (Men)	7	8	16	17	4	54
HBV carriers (Women)	0	0	0	0	0	0
Total number of Acute HBV carriers	8	15	26	29	20	100

Top of Page

Table C.4.ii: Infectious HAV and HBV Cases and HBV Carriers by ORIGIN,
Web-IDSS^† 2005 – 2006.
	Canadian-born	Aboriginal	Foreign-born	Unknown	CSC
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS). 1 – Based on reactive serology result for anti-HAV IgM. 2 – Based on reactive serology result for anti-HBc IgM. 3 – Based on reactive serology result for anti-HBc IgM or HBsAg.
Acute (Active) HAV Cases¹
Acute HAV Cases (New Admissions)	4	3	1	4	12
Acute HAV Cases (General Population)	1	2	1	7	11
Total Acute HAV Cases	5	5	2	11	23
Acute HBV Cases (Active Case)²
Acute HBV Cases (New Admissions)	7	2	2	0	11
Acute HBV Cases (General Population)	6	2	1	5	14
Acute Total Acute HBV Cases	13	4	3	5	25
Infectious HBV Cases (Carrier)³
HBV Carriers (New Admissions)	21	11	12	2	46
HBV Carriers (General Population)	18	13	8	15	54
Total Acute HBV Carriers	39	24	20	17	100

Appendix D:
Sexually Transmitted Infections (STI)

Table D.1.i: Chlamydia Case Reports among Inmates in Canadian Federal Penitentiaries by
Gender and Region, IDSS^†, 2005 - 2006.
Chlamydia	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC
Chlamydia	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS)
No. of Positive Test Reports	14	8	20	10	5	7	52	69	1	1	92	95
Male Cases	14	7	19	9	4	6	49	64	1	1	87	87
Male Prevalence Rate	1.24%	0.57%	0.64%	0.28%	0.13%	0.17%	1.77%	2.14%	0.06%	0.05%	0.74%	0.68%
Female Cases	0	1	1	1	1	1	3	5	0	0	5	8
Female Prevalence Rate	0.00%	1.67%	1.43%	1.22%	0.96%	0.96%	2.38%	3.42%	0.00%	0.00%	1.29%	1.8%
Overall Prevalence Rate	1.20%	0.62%	0.66%	0.30%	0.15%	0.19%	1.79%	2.20%	0.05%	0.05%	0.75%	0.72%

**Table D.1.ii: Chlamydia History, Testing and Outcome by GENDER and REGION Web-IDSS^† 2005 - 2006.**
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC^1a		CSC^1b
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) ‡ -Numbers of new admissions / general population inmates in the enhanced surveillance system 1a – For New Admissions: includes 41 Region unknown (38 males and 3 females); For General Population: includes 34 Region unknown (34 males and 0 females) 1b – For New Admissions: includes 16 gender unknown; For General Population: includes 7 gender unknown
Number of New Admissions^‡	410	51	948	45	2,229	1	1,474	174	417	34	5,516	308	5,840
Previous chlamydia Test	59	23	265	25	125	0	435	86	67	11	959	147	1,107
Previous Test Uptake	14.4%	45.1%	28.0%	55.6%	5.6%	0.0%	29.5%	49.4%	16.1%	32.4%	17.4%	47.7%	19.0%
Previous Positive chlamydia	11	6	39	4	26	0	103	30	28	3	208	44	253
Previous Test Positivity	18.6%	26.1%	14.7%	16.0%	20.8%	–	23.7%	34.9%	41.8%	27.3%	21.7%	29.9%	22.9%
Previous chlamydia Treated	8	4	34	2	23	0	78	24	22	3	165	33	198
Proportion Treated	72.7%	66.7%	87.2%	50.0%	88.5%	–	75.7%	80.0%	78.6%	100.0%	79.3%	75.0%	78.3%
Chlamydia Test on Admission	86	30	576	35	263	0	903	128	29	5	1,864	199	2,068
Testing Uptake	21.0%	58.8%	60.8%	77.8%	11.8%	0.0%	61.3%	73.6%	7.0%	14.7%	33.8%	64.6%	35.4%
Positive on Admission	1	1	13	1	0	0	54	1	0	0	68	3	72
Test Positivity	1.6%	5.9%	3.0%	11.1%	0.0%	–	8.0%	1.5%	0.0%	0.0%	5.7%	3.2%	5.5%
LIFETIME PREVALENCE Among New Admissions	2.9%	13.7%	5.5%	11.1%	1.2%	0.0%	10.7%	17.8%	6.7%	8.8%	5.0%	15.3%	5.6%
Number General Population^‡	389	24	646	12	928	2	997	97	598	39	3,592	174	3,773
Chlamydia Tests Among General Population	216	10	266	6	62	0	409	56	105	13	1,074	85	1,159
Chlamydia Testing Uptake	55.5%	41.7%	41.2%	50.0%	6.7%	0.0%	41.0%	57.7%	17.6%	33.3%	29.9%	48.9%	30.7%
Positive Result	3	0	4	0	1	0	19	1	2	1	29	2	31
Test Positivity	1.7%	0.0%	2.2%	0.0%	2.7%	–	6.8%	2.1%	2.9%	12.5%	3.8%	3.0%	3.8%
Population Prevalence Estimate	0.8%	0.0%	0.6%	0.0%	0.1%	0.0%	1.9%	1.0%	0.3%	2.6%	0.8%	1.1%	0.8%

**Table D.1.iii: Chlamydia History, Testing and Outcome by ORIGIN Web-IDSS^† 2005 - 2006.**
	Canadian	Aboriginal	Foreign-born	Unknown	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) ‡ -Numbers of new admissions / general population inmates in enhanced surveillance system
Number of New Admissions^‡	3,355	1,007	602	876	5,840
Previous chlamydia Test	567	311	68	161	1,107
Previous Test Uptake	16.9%	30.9%	11.3%	18.4%	19.0%
Previous Positive chlamydia	117	87	15	34	253
Previous Test Positivity	20.6%	28.0%	22.1%	21.1%	22.9%
Previous chlamydia Treated	93	70	13	22	198
Proportion Treated	79.5%	80.5%	86.7%	64.7%	78.3%
Chlamydia Test on Admission	1,107	526	137	298	2,068
Testing Uptake	33.0%	52.2%	22.8%	34.0%	35.4%
Positive On Admission	30	26	2	14	72
Test Positivity	4.5%	6.9%	3.2%	7.3%	5.5%
Lifetime Prevalence	4.4%	11.2%	2.8%	5.5%	5.6%
Number General Population^‡	1,801	836	260	876	3,773
Chlamydia Tests Among General Population	508	322	61	268	1,159
Chlamydia testing uptake	28.2%	38.5%	23.5%	30.6%	30.7%
Positive result	11	14	2	4	31
Test positivity	3.1%	6.0%	4.7%	2.1%	3.8%
Population prevalence estimate	0.6%	1.7%	0.8%	0.5%	0.8%

Table D.2.i: Gonorrhea Case Reports among Inmates in Canadian Federal Penitentiaries by
GENDER and REGION, IDSS^† 2005 - 2006.
Gonorrhea	Atlantic		Quebec		Ontario		Prairie		Pacific		Canada
Gonorrhea	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS)
No. of Positive Test Reports	0	0	0	3	0	2	11	15	0	0	11	20
Male Cases	0	0	0	3	0	1	10	15	0	0	10	19
Male Prevalence Rate	0.00%	0.00%	0.00%	0.09%	0.00%	0.03%	0.36%	0.50%	0.00%	0.00%	0.08%	0.15%
Female Cases	0	0	0	0	0	1	1	0	0	0	1	1
Female Prevalence Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.96%	0.79%	0.00%	0.00%	0.00%	0.26%	0.22%
Overall Prevalence Rate	0.00%	0.00%	0.00%	0.09%	0.00%	0.06%	0.38%	0.48%	0.00%	0.00%	0.09%	0.15%

Top of Page

**Table D.2.ii: Gonorrhea History, Testing and Outcome by GENDER and REGION Web-IDSS^† 2005 - 2006.**
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC^1a		CSC^1b
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) ‡ -Numbers of new admissions / general population inmates in the enhanced surveillance system 1a – For New Admissions: includes 41 Region unknown (38 males and 3 females); For General Population: includes 34 Region unknown (34 males and 0 females) 1b – For New Admissions: includes 16 gender unknown; For General Population: includes 7 gender unknown
Number of new admissions^‡	410	51	948	45	2,229	1	1,474	174	417	34	5,516	308	5,840
Previous gonorrhea Test	49	23	258	24	122	0	390	80	55	11	880	140	1,020
Previous Test Uptake	12.0%	45.1%	27.2%	53.3%	5.5%	0.0%	26.5%	46.0%	13.2%	32.4%	16.0%	45.5%	17.5%
Previous Positive gonorrhea	3	1	22	4	18	0	45	15	17	0	106	21	127
Previous Test Positivity	6.1%	4.3%	8.5%	16.7%	14.8%	–	11.5%	18.8%	30.9%	0.0%	12.0%	15.0%	12.5%
Previous gonorrhea Treated	2	0	18	4	17	0	37	9	13	0	88	13	101
Proportion Treated	66.7%	0.0%	81.8%	100.0%	94.4%	–	82.2%	60.0%	76.5%	–	83.0%	61.9%	79.5%
Gonorrhea Test on Admission	84	30	582	35	254	0	844	127	30	5	1,800	198	2,003
Testing Uptake	20.5%	58.8%	61.4%	77.8%	11.4%	0.0%	57.3%	73.0%	7.2%	14.7%	32.6%	64.3%	34.3%
Positive on Admission	0	0	0	1	0	0	9	1	0	0	9	2	11
Test Positivity	0.0%	0.0%	0.0%	12.5%	0.0%	–	1.5%	1.5%	0.0%	0.0%	0.8%	2.1%	0.9%
LIFETIME PREVALENCE	0.7%	2.0%	2.3%	11.1%	0.8%	0.0%	3.7%	9.2%	4.1%	0.0%	2.1%	7.5%	2.4%
Number General Population^‡	389	24	646	12	928	2	997	97	598	39	3,592	174	3,773
Gonorrhea Tests Among General Population	211	10	240	6	54	0	375	54	102	12	997	82	1,079
Gonorrhea Testing Uptake	54.2%	41.7%	37.2%	50.0%	5.8%	0.0%	37.6%	55.7%	17.1%	30.8%	27.8%	47.1%	28.6%
Positive Result	0	0	0	0	0	0	5	0	0	0	5	0	5
Test Positivity	0.0%	0.0%	0.0%	0.0%	0.0%	–	2.0%	0.0%	0.0%	0.0%	0.7%	0.0%	0.7%
Population Prevalence Estimate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.5%	0.0%	0.0%	0.0%	0.1%	0.0%	0.1%

Table D.2.iii: Gonorrhea History, Testing and Outcome by
ORIGIN and REGION Web-IDSS^† 2005 - 2006.
	Canadian	Aboriginal	Foreign-born	Unknown	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) ‡ -Numbers of new admissions / general population inmates in enhanced surveillance system
Number of New Admissions^‡	3,355	1,007	602	876	5,840
Previous Gonorrhea Test	514	293	122	150	1,020
Previous Test Uptake	15.3%	29.1%	5.5%	17.1%	17.5%
Previous Positive Gonorrhea	57	42	18	19	127
Previous Test Positivity	11.1%	14.3%	14.8%	12.7%	12.5%
Previous Gonorrhea Treated	45	30	17	17	101
Proportion Treated	78.9%	71.4%	94.4%	89.5%	79.5%
Gonorrhea Test on Admission	1,073	506	254	287	2,003
Testing Uptake	32.0%	50.2%	11.4%	32.8%	34.3%
Positive on Admission	6	2	0	3	11
Test Positivity	1.0%	0.6%	0.0%	1.6%	0.9%
LIFETIME PREVALENCE	1.9%	4.4%	0.8%	2.5%	2.4%
Number General Population	1,801	836	928	876	3,773
Gonorrhea Tests Among General Population	472	297	54	259	1,079
Gonorrhea Testing Uptake	26.2%	35.5%	5.8%	29.6%	28.6%
Positive Result	2	3	0	0	5
Test Positivity	0.2%	0.5%	0.0%	0.0%	0.2%
Population Prevalence Estimate	0.1%	0.4%	0.0%	0.0%	0.1%

Table D.3.i: Syphilis Case Reports among Inmates in Canadian Federal Penitentiaries by
GENDER and REGION, IDSS^†, 2005 - 2006.
Syphilis	Atlantic		Quebec		Ontario		Prairie		Pacific		Canada
Syphilis	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS)
No. of Positive Test Reports	0	0	2	2	2	6	1	3	1	5	6	16
Male Cases	0	0	2	1	2	5	1	3	1	5	6	14
Male Prevalence Rate	0.00%	0.00%	0.07%	0.03%	0.06%	0.14%	0.04%	0.10%	0.06%	0.26%	0.05%	0.11%
Female Cases	0	0	0	1	0	1	0	0	0	0	0	2
Female Prevalence Rate	0.00%	0.00%	0.00%	1.22%	0.00%	0.96%	0.00%	0.00%	0.00%	0.00%	0.00%	0.45%
Overall Prevalence Rate	0.00%	0.00%	0.07%	0.06%	0.06%	0.17%	0.03%	0.10%	0.05%	0.25%	0.05%	0.12%

**Table D.3.ii: Syphilis History, Testing and Outcome by GENDER and REGION Web-IDSS^† 2005 - 2006.**
	Atlantic		Quebec		Ontario		Prairie		Pacific		CSC^1a		CSC^1b
	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Males	Females	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) ‡ -Numbers of new admissions / general population inmates in the enhanced surveillance system * - based on positive serology for VDRL 1a – For New Admissions: includes 41 Region unknown (38 males and 3 females); For General Population: includes 34 Region unknown (34 males and 0 females) 1b – For New Admissions: includes 16 gender unknown; For General Population: includes 7 gender unknown
Number of New Admissions^‡	410	51	948	45	2,229	1	1,474	174	417	34	5,516	308	5,840
Previous syphilis Test	47	15	285	21	375	0	341	74	67	8	1,127	120	1,248
Previous Test Uptake	11.5%	29.4%	30.1%	46.7%	16.8%	0.0%	23.1%	42.5%	16.1%	23.5%	20.4%	39.0%	21.4%
Previous Positive syphilis	1	0	2	1	10	0	9	4	6	0	29	6	36
Previous Test Positivity	2.1%	0.0%	0.7%	4.8%	2.7%	–	2.6%	5.4%	9.0%	0.0%	2.6%	5.0%	2.9%
Previous syphilis Treated	1	0	0	1	4	0	5	2	3	0	14	3	17
Proportion Treated	100.0%	–	0.0%	100.0%	40.0%	–	55.6%	50.0%	50.0%	–	48.3%	50.0%	47.2%
Syphilis Test on Admission	135	39	829	41	1,283	1	923	146	140	12	3,331	241	3,580
Syphilis Testing Uptake	32.9%	76.5%	87.4%	91.1%	57.6%	100.0%	62.6%	83.9%	33.6%	35.3%	60.4%	78.2%	61.3%
Positive Result*	0	0	0	0	3	0	0	1	1	0	4	1	5
Test Positivity	0.0%	0.0%	0.0%	0.0%	0.6%	–	0.0%	1.1%	1.1%	0.0%	0.2%	0.6%	0.2%
Lifetime Prevalence	0.2%	0.0%	0.2%	2.2%	0.6%	0.0%	0.6%	2.9%	1.7%	0.0%	0.6%	2.3%	0.7%
Number General Population‡	389	24	646	12	928	2	997	97	598	39	3,592	174	3,773
Syphilis Tests Among General Population	230	13	331	11	423	1	556	77	221	17	1,784	119	1,906
Syphilis Testing Uptake	59.1%	54.2%	51.2%	91.7%	45.6%	50. 0%	55.8%	79.4%	37.0%	43.6%	49.7%	68.4%	50.5%
Positive Result*	2	0	1	1	0	0	1	0	1	0	5	1	6
Test Positivity	1.1%	0.0%	0.4%	10.0%	0.0%	0.0%	0.2%	0.0%	0.7%	0.0%	0.4%	1.1%	0.4%
Population Prevalence Estimate	0.5%	0.0%	0.2%	8.3%	0.0%	0.0%	0.1%	0.0%	0.2%	0.0%	0.1%	0.6%	0.2%

Top of Page

**Table D.3.iii: Syphilis History, Testing and Outcome by ORIGIN Web-IDSS^† 2005 - 2006.**
	Canadian	Aboriginal	Foreign-born	Unknown	Total
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) ‡ - Numbers of new admissions / general population inmates in enhanced surveillance system * - based on positive serology for VDRL
Number of New Admissions^‡	3,355	1,007	602	876	5,840
Previous syphilis Test	677	296	87	188	1,248
Previous Test Uptake	20.2%	29.4%	14.5%	21.5%	21.4%
Previous Positive syphilis	12	13	3	8	36
Previous Test Positivity	1.8%	4.4%	3.4%	4.3%	2.9%
Previous syphilis Treated	5	7	2	3	17
Proportion Treated	41.7%	53.8%	66.7%	37.5%	47.2%
Syphilis Test on Admission	2,033	686	344	517	3,580
Testing Uptake	60.6%	68.1%	57.1%	59.0%	61.3%
Positive Result*	1	2	2	0	5
Test Positivity	0.1%	0.4%	1.2%	0.0%	0.2%
Lifetime Prevalence	0.4%	1.5%	0.8%	0.9%	0.7%
Number General Population	1,801	836	260	876	3,773
Syphilis Tests Among General Population	917	451	130	408	1,906
Syphilis Testing Uptake	50.9%	53.9%	50.0%	46.6%	50.5%
Positive Result*	3	1	0	2	6
Test Positivity	0.4%	0.3%	0.0%	0.7%	0.4%
Population Prevalence Estimate	0.2%	0.1%	0.0%	0.2%	0.2%

Appendix E:
Tuberculosis Screening - Inmates

**Table E.1: Reported TST Results on Initial Assessment by REGION – Inmates, Web-IDSS^† 2005 - 2006**
Freq (%) TST Result	Atlantic		Quebec		Ontario		Prairie		Pacific		Canada⁴
Freq (%) TST Result	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Medically contraindicated (i.e., tuberculin allergy, etc) 2 - An invalid first TST includes a 'No show' for the read portion of the test or a negative read after 72 hours. 3 - An invalid second TST includes a 'No show' for the read portion of the test, a negative read after 72 hours, a second test not done, or a test administered outside of the 7 to 365 days of the first tuberculin administration. 4 - Total assessments for CSC overall (Canada) include 'Unknown' region (data not shown)for 2005 (N=56) and 2006 (N=181)
Tested Positive	25 (6.3%)	18 (4.5%)	184 (23.5%)	184 (27.3%)	67 (6.4%)	103 (12.0%)	96 (12.5%)	100 (10.7%)	20 (5.0%)	28 (8.0%)	401 (11.6%)	446 (13.3%)
Tested Negative	375 (93.8%)	386 (95.5%)	600 (76.5%)	491 (72.7%)	981 (93.6%)	752 (88.0%)	674 (87.5%)	836 (89.3%)	382 (95.0%)	321 (92.0%)	3,047 (88.4%)	2,914 (86.7%)
Previous Positive	6	10	11	11	4	7	34	18	6	4	61	52
Contraindicated¹	2	2	13	11	10	10	7	13	4	0	36	37
Invalid	65 (12.9%)	67 (13.0%)	57 (5.6%)	118 (12.4%)	58 (4.5%)	137 (12.2%)	157 (14.8%)	217 (17.3%)	35 (7.3%)	36 (8.7%)	379 (8.6%)	605 (13.6%)
Invalid TST-1²	21	27	13	35	18	27	48	70	10	12	111	178
Invalid TST-2³	44	40	44	83	40	110	109	147	25	24	268	427
Refused TST	11 (2.2%)	10 (1.9%)	83 (8.1%)	88 (9.2%)	8 (0.6%)	5 (0.4%)	30 (2.8%)	17 (1.4%)	8 (1.7%)	1 (0.2%)	141 (3.2%)	121 (2.7%)
Blank / Unknown	20	21	73	50	147	107	60	55	23	22	327	262
TOTAL (%)	504 (11.5%)	514 (11.6%)	1,021 (23.2%)	953 (21.5%)	1,275 (29.0%)	1,121 (25.3%)	1,058 (24.1%)	1,256 (28.3%)	478 (10.9%)	412 (9.3%)	4,392	4,437

**Table E.2: BCG Vaccination Status¹ by ORIGIN and REGION – Inmates, Web-IDSS^† 2005 - 2006**
Freq (%) Origin	Atlantic		Quebec		Ontario		Prairie		Pacific		Canada
Freq (%) Origin	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 – Percentage who report a history of BCG vaccination on Initial Assessment (as part of the TB medical history).
Canadian Born	1.0%	1.0%	32.1%	27.5%	1.2%	2.6%	7.0%	6.5%	10.1%	2.5%	11.6%	9.6%
Aboriginal	5.9%	3.4%	23.2%	18.2%	1.5%	4.0%	11.8%	10.2%	17.5%	0.0%	11.1%	8.0%
Foreign Born	4.4%	7.7%	17.6%	20.5%	15.8%	13.3%	17.9%	25.6%	10.3%	6.5%	15.0%	16.2%
Unknown	0.0%	0.0%	20.0%	16.7%	2.4%	5.2%	4.8%	12.9%	4.4%	4.6%	8.3%	9.6%
Total (%)	1.4%	4.3%	29.0%	24.9%	4.2%	5.0%	9.2%	10.0%	10.7%	2.7%	11.6%	9.9%

**Table E.3: Reported TST Results on Ongoing Negative Assessment by REGION – Inmates, Web-IDSS^† 2005 - 2006**
Freq (%) TST Result	Atlantic		Quebec		Ontario		Prairie		Pacific		Canada³
Freq (%) TST Result	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Medically contraindicated (i.e., tuberculin allergy, etc) 2 - An invalid first TST includes a 'No show' for the read portion of the test or a negative read after 72 hours. 3 - Totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=116) and 2006 (N=244)
Tested Positive	7 (1.0%)	5 (0.7%)	9 (0.8%)	17 (1.3%)	13 (0.9%)	13 (0.7%)	48 (2.5%)	45 (2.4%)	14 (1.8%)	19 (2.2%)	93 (1.5%)	103 (1.5%)
Tested Negative	678 (99.0%)	683 (99.3%)	1,143 (99.2%)	1,280 (98.7%)	1,498 (99.1%)	1,935 (99.3%)	1,853 (97.5%)	1,804 (97.6%)	748 (98.2%)	845 (97.8%)	6,007 (98.5%)	6,753 (98.5%)
Contraindicated¹	3	5	5	20	55	23	12	14	5	6	80	68
Invalid TST-1²	23 (2.9%)	22 (2.8%)	63 (3.8%)	32 (1.8%)	58 (2.5%)	45 (1.6%)	62 (2.8%)	85 (3.6%)	84 (7.7%)	94 (8.7%)	297 (3.6%)	287 (3.2%)
Refused TST	48 (6.1%)	38 (4.8%)	275 (16.8%)	286 (16.0%)	73 (3.1%)	78 (2.8%)	104 (4.7%)	126 (5.3%)	86 (7.9%)	58 (5.4%)	591 (7.2%)	599 (6.6%)
Blank / Unknown	34	39	146	150	631	654	136	298	149	54	1,111	1,207
TOTAL (%)	793 (9.7%)	792 (8.8%)	1,641 (20.1%)	1,758 (19.8%)	2,328 (28.5%)	2,748 (30.5%)	2,215 (27.1%)	2,372 (26.3%)	1,086 (13.3%)	1,076 (11.9%)	8,179	9,017

**Table E.4: LTBI¹ by AGE GROUP and REGION – Inmates, Web-IDSS^† 2005 - 2006**
Freq (%)² Age Group	Atlantic		Quebec		Ontario		Prairie		Pacific		Canada³
Freq (%)² Age Group	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Includes all inmates with positive TST result, either newly diagnosed on Initial and Ongoing Negative Assessments, Previous positive on Initial Assessment, and Ongoing Positive Assessments. 2 – Frequency calculated by dividing the number positive by the number of inmates participating in TB screening per age group and region. 3 – LTBI totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=191) and 2006 (N=443).
Missing	3 (25.0%)	0 (0.0%)	1 (50.0%)	1 (14.3%)	1 (9.1%)	1 (9.1%)	0 (0.0%)	2 (7.1%)	2 (18.2%)	1 (8.3%)	8 (11.9%)	5 (6.3%)
17-19	1 (2.6 %)	1 (2.6%)	6 (17.1%)	8 (30.8%)	4 (10.0%)	6 (17.6%)	9 (10.2%)	3 (4.2%)	2 (15.4%)	1 (7.1%)	22 (10.2%)	20 (10.5%)
20-29	11 (2.3%)	12 (2.6%)	71 (10.3%)	81 (11.6%)	81 (7.0%)	132 (11.1%)	180 (12.0%)	175 (10.6%)	26 (5.8%)	28 (7.3%)	379 (8.7%)	435 (9.7%)
30-39	25 (6.5%)	21 (5.4%)	154 (14.7%)	182 (17.4%)	159 (12.6%)	178 (14.6%)	197 (18.0%)	216 (18.5%)	41 (8.2%)	44 (9.3%)	583 (13.4%)	655 (14.8%)
40-49	39 (14.4%)	31 (11.0%)	252 (28.3%)	287 (29.8%)	162 (16.5%)	172 (17.2%)	206 (29.4%)	182 (23.7%)	59 (15.4%)	54 (14.5%)	734 (22.3%)	739 (21.2%)
50-59	24 (20.5%)	30 (23.3%)	134 (38.7%)	164 (41.2%)	64 (17.7%)	99 (24.9%)	74 (36.3%)	71 (29.7%)	29 (16.5%)	39 (23.1%)	331 (27.1%)	418 (30.0%)
60 +	9 (18.8%)	4 (10.0%)	44 (40.0%)	65 (42.8%)	43 (25.3%)	42 (26.4%)	25 (36.8%)	20 (29.4%)	19 (27.9%)	15 (21.7%)	141 (29.9%)	149 (29.6%)
TOTAL (%)	112 (8.3%)	99 (7.3%)	662 (21.2%)	788 (23.9%)	514 (12.9%)	630 (15.7%)	691 (18.7%)	669 (16.8%)	178 (11.1%)	182 (12.2%)	2,198 (15.8%)	2,421 (16.6%)

**Table E.5: LTBI¹ by ORIGIN and REGION – Inmates, Web-IDSS^† 2005 - 2006**
Freq (%)² Origin	Atlantic		Quebec		Ontario		Prairie		Pacific		Canada³
Freq (%)² Origin	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Includes all inmates with a positive TST result, either newly diagnosed on Initial or Ongoing Negative Assessments, Previous positive on Initial Assessment, or Ongoing Positive Assessments. 2 – Frequency calculated by dividing the number positive by the number of inmates participating in TB screening per origin group and region. 3 – LTBI totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=191) and 2006 (N=443).
Canadian Born	50 (6.2%)	32 (3.8%)	288 (16.6%)	357 (19.3%)	130 (6.6%)	195 (9.4%)	106 (9.2%)	97 (7.4%)	27 (4.4%)	34 (5.8%)	612 (9.6%)	735 (10.7%)
Aboriginal	13 (12.6%)	17 (14.3%)	48 (23.4%)	47 (23.0%)	74 (16.0%)	51 (13.7%)	388 (24.1%)	371 (23.2%)	50 (14.3%)	48 (14.9%)	588 (21.2%)	542 (20.0%)
Foreign Born	12 (37.5%)	7 (30.4%)	80 (43.0%)	104 (49.5%)	156 (29.5%)	213 (41.4%)	59 (45.4%)	62 (38.5%)	39 (36.1%)	35 (42.7%)	355 (35.6%)	433 (42.5%)
Unknown	37 (8.8%)	43 (11.2%)	246 (24.8%)	280 (27.2%)	154 (15.1%)	171 (16.2%)	138 (17.3%)	139 (15.2%)	62 (11.8%)	65 (12.9%)	643 (16.9%)	711 (17.8%)
Total (%)	112 (8.3%)	99 (7.3%)	662 (21.2%)	788 (23.9%)	514 (12.9%)	630 (15.7%)	691 (18.7%)	669 (16.8%)	178 (11.1%)	182 (12.2%)	2,198 (15.8%)	2,421 (16.6%)

Top of Page

**Table E.6: LTBI¹ by GENDER and REGION – Inmates, Web-IDSS^† 2005 - 2006**
Freq (%)² Gender	Atlantic		Quebec		Ontario		Prairie		Pacific³		Canada⁴
Freq (%)² Gender	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Includes all inmates with a positive TST result, either newly diagnosed on Initial or Ongoing Negative Assessments, Previous positive on Initial Assessment, or Ongoing Positive Assessments. 2 – Frequency calculated by dividing the number positive by the number of inmates participating in TB screening per gender and region. 3 – Prior to April 1st 2004, federally sentenced women in Pacific region were generally kept in a provincial institution. 4 – LTBI totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=191) and 2006 (N=443).
Male	108 (8.4%)	89 (7.0%)	647 (21.6%)	782 (24.4%)	506 (13.2%)	618 (16.0%)	668 (19.1%)	642 (17.0%)	177 (11.2%)	182 (12.2%)	2,150 (16.1%)	2,349 (16.8%)
Female	4 (6.0%)	10 (10.9%)	6 (7.0%)	5 (6.3%)	8 (5.3%)	10 (7.0%)	23 (11.7%)	26 (12.7%)	1 (7.1%)	0 (0.0%)	47 (8.4%)	68 (11.3%)
Unknown	0 (0.0%)	0 (0.0%)	1 (33.3%)	1 (33.3%)	0 (0.0%)	2 (20.0%)	0 (0.0%)	1 (9.1%)	0 (0.0%)	0 (0.0%)	1 (5.6%)	4 (12.5%)
Total (%)	112 (8.3%)	99 (7.3%)	662 (21.2%)	788 (23.9%)	514 (12.9%)	630 (15.7%)	691 (18.7%)	669 (16.8%)	178 (11.1%)	182 (12.2%)	2,198 (15.8%)	2,421 (16.6%)

Table E.7.i: Reported Comorbidity / Risk Factors¹ and Symptoms¹ by TST Result –
Inmates, Web-IDSS^† 2005
Test Type	Positive²	Previous Positive³	Ongoing Positive	Sub-Total	Negative	Other⁴	Sub-total	TOTAL
	N= 494	N= 61	N= 1,643	N= 2,198	N= 9,054	N= 2,962	N= 12,016	N= 14,214
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Numbers in the table reflect those answering 'Yes' to the risk factor / symptom (individuals may report multiple risk factors / symptoms). 2 - Includes newly positive TST results from Initial and Ongoing Negative assessments. 3 – Previously positive TST accepted on Initial Assessment – see Table E.1. 4 - 'Other' result includes medically contraindicated, invalid TST-1, invalid TST-2 (second of two-step TST), refused, and blank/unknown.
Risks
Diabetes	14	2	63	79	193	47	240	319
	(2.83%)	(3.28%)	(3.83%)	(3.59%)	(2.13%)	(1.59%)	(2.00%)	(2.24%)
Hemodialysis	0	0	2	2	12	2	14	16
	(0.0%)	(0.0%)	(0.12%)	(0.09%)	(0.13%)	(0.07%)	(0.12%)	(0.11%)
Silicosis	1	0	3	4	4	1	5	9
	(0.2%)	(0.0%)	(0.18%)	(0.18%)	(0.04%)	(0.03%)	(0.04%)	(0.06%)
Transplant	1	0	5	6	15	3	18	24
	(0.2%)	(0.0%)	(0.30%)	(0.27%)	(0.17%)	(0.1%)	(0.15%)	(0.17%)
Injection Drug User	58	8	138	204	1121	335	1,456	1,660
	(11.74%)	(13.11%)	(8.4%)	(9.28%)	(12.38%)	(11.31%)	(12.12%)	(11.68%)
Lymphoma	3	0	4	7	14	6	20	27
	(0.61%)	(0.0%)	(0.24%)	(0.32%)	(0.15%)	(0.2%)	(0.17%)	(0.19%)
HIV/AIDS	1	1	17	19	147	40	187	206
	(0.2%)	(1.64%)	(1.03%)	(0.86%)	(1.62%)	(1.35%)	(1.56%)	(1.45%)
Chemotherapy	2	1	5	8	60	13	73	81
	(0.4%)	(1.64%)	(0.3%)	(0.36%)	(0.66%)	(0.44%)	(0.61%)	(0.57%)
Steroids	7	1	13	21	166	50	26	237
	(1.42%)	(1.64%)	(0.79%)	(0.96%)	(1.83%)	(1.69%)	(1.80%)	(1.67%)
TB Case Contact	11	2	45	58	118	49	167	225
	(2.23%)	(3.28%)	(2.74%)	(2.64%)	(1.30%)	(1.65%)	(1.39%)	(1.58%)
TOTAL	98	15	295	408	1,850	546	2,396	2,804
Symptoms
Fatigue	33	6	143	182	493	211	704	886
	(6.68%)	(9.84%)	(8.70%)	(8.28%)	(5.45%)	(7.12%)	(5.86%)	(6.23%)
Fever	6	0	17	23	59	22	81	104
	(1.21%)	(0.0%)	(1.03%)	(1.05%)	(0.65%)	(0.74%)	(0.67%)	(0.73%)
Weight Loss	14	1	67	82	259	83	342	424
	(2.83%)	(1.64%)	(4.08%)	(3.73%)	(2.86%)	(2.8%)	(2.85%)	(2.98%)
Loss of Appetite	20	0	82	102	286	73	359	461
	(4.05%)	(0.0%)	(4.99%)	(4.64%)	(3.16%)	(2.46%)	(2.99%)	(3.24%)
Night Sweats	32	1	76	109	334	72	406	515
	(6.478%)	(1.64%)	(4.63%)	(4.96%)	(3.69%)	(2.43%)	(3.38%)	(3.62%)
Hoarseness	20	1	61	82	183	41	224	306
	(4.05%)	(1.64%)	(3.71%)	(3.73%)	(2.02%)	(1.38%)	(1.86%)	(2.15%)
Productive Cough	21	2	115	138	312	79	391	529
	(4.25%)	(3.28%)	(7.00%)	(6.28%)	(3.45%)	(2.67%)	(3.25%)	(3.72%)
Coughing Blood	4	0	20	24	52	14	66	90
	(0.81%)	(0.0%)	(1.22%)	(1.09%)	(0.57%)	(0.47%)	(0.55%)	(0.63%)
Chest Pains	20	4	122	146	409	118	527	673
	(4.05%)	(6.56%)	(7.43%)	(6.64%)	(4.52%)	(3.98%)	(4.39%)	(4.73%)
Total	170	15	703	888	2,387	713	3,100	3,988

Table E.7.ii: Reported Comorbidity / Risk Factors¹ and Symptoms¹ by TST Result –
Inmates, Web-IDSS^† 2006
Test Type	Positive²	Previous Positive³	Ongoing Positive	Sub-Total	Negative	Other⁴	Sub-total	TOTAL
	N= 549	N= 52	N= 1,820	N= 2,421	N= 9,667	N= 3,186	N= 12,853	N= 15,274
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Numbers in the table reflect those answering 'Yes' to the risk factor / symptom (individuals may report multiple risk factors / symptoms). 2 - Includes newly positive TST results from Initial and Ongoing Negative assessments. 3 – Previously positive TST accepted on Initial Assessment – see Table E.1. 4 - 'Other' result includes medically contraindicated, invalid TST-1, invalid TST-2 (second of two-step TST), refused, and blank/unknown.
Risks
Diabetes	23	2	97	122	291	89	380	502
	(4.19%)	(3.85%)	(5.33%)	(5.04%)	(3.01%)	(2.79%)	(2.96%)	(3.29%)
Hemodialysis	1	0	2	3	14	6	20	23
	(0.18%)	(0.0%)	(0.11%)	(0.12%)	(0.14%)	(0.19%)	(0.16%)	(0.15%)
Silicosis	0	0	1	1	3	3	6	7
	(0.0%)	(0.0%)	(0.05%)	(0.04%)	(0.03%)	(0.09%)	(0.05%)	(0.05%)
Transplant	3	0	4	7	16	6	22	29
	(0.55%)	(0.0%)	(0.22%)	(0.29%)	(0.17%)	(0.19%)	(0.17%)	(0.19%)
Injection Drug User	75	6	186	267	1,335	391	1,726	1,993
	(13.68%)	(11.54%)	(10.22%)	(11.03%)	(13.81%)	(12.27%)	(13.43%)	(13.05%)
Lymphoma	1	0	4	5	15	4	19	24
	(0.18%)	(0.0%)	(0.22%)	(0.21%)	(0.16%)	(0.13%)	(0.15%)	(0.16%)
HIV/AIDS	3	1	20	24	153	45	198	222
	(0.55%)	(1.92%)	(1.10%)	(0.99%)	(1.58%)	(1.41%)	(1.54%)	(1.45%)
Chemotherapy	4	0	9	13	59	15	74	87
	(0.73%)	(0.0%)	(0.49%)	(0.54%)	(0.61%)	(0.47%)	(0.58%)	(0.57%)
Steroids	4	1	21	26	221	52	273	299
	(0.73%)	(1.92%)	(1.15%)	(1.07%)	(2.29%)	(1.63%)	(2.12%)	(1.96%)
TB Case Contact	10	2	85	97	319	60	379	476
	(1.82%)	(3.85%)	(4.67%)	(4.01%)	(3.30%)	(1.88%)	(2.95%)	(3.12%)
Total	124	12	429	565	2,426	671	3,097	3,662
Symptoms
Fatigue	25	4	116	145	484	199	603	748
	(4.55%)	(7.69%)	(6.37%)	(5.99%)	(5.01%)	(3.74%)	(4.69%)	(4.90%)
Fever	6	0	20	26	62	21	83	109
	(1.09%)	(0.0%)	(1.10%)	(1.07%)	(0.64%)	(0.66%)	(0.65%)	(0.71%)
Weight Loss	11	2	76	89	299	93	392	481
	(2.00%)	(3.85%)	(4.18%)	(3.68%)	(3.09%)	(2.92%)	(3.05%)	(3.15%)
Loss of Appetite	20	2	87	109	300	87	387	496
	(3.64%)	(3.85%)	(4.78%)	(4.50%)	(3.10%)	(2.73%)	(3.01%)	(3.25%)
Night Sweats	17	1	78	96	331	80	411	507
	(3.10%)	(1.92%)	(4.29%)	(3.97%)	(3.42%)	(2.51%)	(3.20%)	(3.32%)
Hoarseness	12	0	57	69	147	41	188	257
	(2.19%)	(0.0%)	(3.13%)	(2.85%)	(1.52%)	(1.29%)	(1.46%)	(1.68%)
Productive Cough	13	3	103	119	322	74	396	515
	(2.37%)	(5.77%)	(5.66%)	(4.92%)	(3.33%)	(2.32%)	(3.08%)	(3.37%)
Coughing Blood	3	0	11	14	62	24	86	100
	(0.55%)	(0.0%)	(0.60%)	(0.58%)	(0.64%)	(0.75%)	(0.67%)	(0.65%)
Chest Pains	28	3	95	126	389	108	497	623
	(5.10%)	(5.77%)	(5.22%)	(5.20%)	(4.02%)	(3.39%)	(3.87%)	(4.08%)
Total	135	15	643	793	2,396	647	3,043	3,836

**Table E.8: Treatment Uptake for Latent Tuberculosis Infection – Inmates, IDSS^† 2005 - 2006**
Freq (%) Gender	Atlantic		Quebec		Ontario		Prairie		Pacific		Canada
Freq (%) Gender	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Aggregate Infectious Disease Surveillance System (IDSS)
Number of Inmates with LTBI	109	99	654	777	507	627	683	653	171	181	2,165	2,389
Average Number on LTBI Therapy per Month	4	3	8	5	53	50	21	32	13	15	99	103

Top of Page

Appendix F:
Tuberculosis Screening - Staff

**Table F.1: Reported TST Results on Initial Assessment by REGION – Staff, Web-IDSS^† 2005 - 2006**
Freq (%) TST Result	Atlantic		Quebec		Ontario		Prairie		Pacific		Canada⁴
Freq (%) TST Result	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Medically contraindicated (i.e., tuberculin allergy etc) 2 - An invalid first TST includes a 'No show' for the read portion of the test or a negative read after 72 hours. 3 - An invalid second TST includes a 'No show' for the read portion of the test, a negative read after 72 hours, a second test not done, or a test administered outside of the 7 to 365 days of the first tuberculin administration. 4 – Total assessments for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=155) and 2006 (N=86)
Tested Positive	2 (11.8%)	4 (6.9%)	9 (22.5%)	10 (19.2%)	3 (5.1%)	4 (3.0%)	5 (13.2%)	6 (3.9%)	0 (0.0%)	1 (2.9%)	23 (8.2%)	28 (5.7%)
Tested Negative	15 (88.2%)	54 (93.1%)	31 (77.5%)	42 (80.8%)	56 (94.9%)	131 (97.0%)	32 (86.5%)	147 (96.1%)	1 (100%)	34 (97.1%)	258 (91.8%)	463 (94.3%)
Previous Positive	1	4	1	2	2	5	1	12	2	3	10	21
Contraindicated¹	0	0	0	0	0	0	0	1	0	0	0	2
Invalid	11 (37.9%)	6 (8.8%)	15 (25.4%)	4 (6.9%)	22 (26.2%)	14 (8.8%)	21 (34.4%)	51 (22.5%)	13 (72.2%)	24 (37.5%)	105 (25.9%)	118 (17.8%)
Invalid TST-1²	0	2	3	0	4	2	2	8	6	7	22	23
Invalid TST-2³	11	4	12	4	18	12	19	43	7	17	83	95
Refused TST	0 (0.0%)	0 (0.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	2 (0.3%)
Blank / Unknown	0	0	2	0	1	6	2	10	2	2	9	23
TOTAL (%)	29 (7.1%)	68 (10.3%)	59 (14.5%)	58 (8.7%)	84 (20.7%)	160 (24.1%)	61 (15.0%)	227 (34.2%)	18 (4.4%)	64 (9.7%)	406	663

**Table F.2: BCG Vaccination Status¹ by ORIGIN and REGION – Inmates Staff, Web-IDSS^† 2005 - 2006**
Freq (%) Origin	Atlantic		Quebec		Ontario		Prairie		Pacific		Canada
Freq (%) Origin	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 – Percentage who report a history of BCG vaccination on Initial Assessment (as part of the TB medical history).
Canadian Born	0.0%	3.5%	28.9%	24.0%	0.0%	8.7%	0.0%	1.8%	8.3%	3.9%	6.4%	6.9%
Aboriginal	0.0%	0.0%	0.0%	100%	0.0%	22.2%	7.7%	0.0%	0.0%	0.0%	6.7%	8.3%
Foreign Born	100%	0.0%	50.0%	0.0%	0.0%	0.0%	0.0%	27.3%	0.0%	28.6%	11.1%	22.2%
Unknown	0.0%	12.5%	50.0%	25.0%	25.0%	9.1%	0.0%	9.1%	33.3%	0.0%	25.0%	12.2%
Total (%)	3.5%	4.4%	33.9%	24.1%	2.4%	9.4%	1.6%	3.1%	11.1%	6.3%	8.4%	8.0%

**Table F.3: Reported TST Results on Ongoing Negative Assessment by REGION – Staff, Web-IDSS^† 2005 - 2006**
Freq (%) TST Result	Atlantic		Quebec		Ontario		Prairie		Pacific		Canada³
Freq (%) TST Result	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Medically contraindicated (i.e., tuberculin allergy etc) 2 - An invalid first TST includes a 'No show' for the read portion of the test or a negative read after 72 hours. 3 - Totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=164) and 2006 (N=182)
Tested Positive	6 (1.5%)	2 (0.4%)	5 (8.2%)	12 (7.7%)	3 (0.9%)	1 (0.3%)	1 (0.8%)	8 (1.2%)	2 (1.4%)	3 (3.1%)	19 (1.6%)	31 (1.7%)
Tested Negative	385 (98.5%)	494 (99.6%)	56 (91.8%)	144 (92.3%)	341 (99.1%)	320 (99.7%)	124 (99.2%)	643 (98.8%)	137 (98.6%)	93 (96.9%)	1,164 (98.4%)	1,844 (98.3%)
Contraindicated¹	0	0	0	0	0	1	1	6	0	1	1	8
Invalid TST-1²	22 (5.2%)	13 (2.5%)	3 (4.6%)	2 (1.3%)	44 (11.1%)	34 (9.3%)	19 (12.5%)	43 (5.9%)	166 (53.0%)	126 (56.3%)	290 (19.2%)	242 (11.1%)
Refused TST	4 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.7%)	1 (0.1%)	1 (0.3%)	0 (0.0%)	6 (0.4%)	2 (0.1%)
Blank / Unknown	7	5	1	1	8	11	6	34	7	1	34	54
TOTAL (%)	424 (28.0%)	514 (23.6%)	65 (4.3%)	159 (7.3%)	396 (26.2%)	367 (16.8%)	152 (10.0%)	735 (33.7%)	313 (20.7%)	224 (10.3 %)	1,514	2,181

**Table F.4: LTBI¹ by AGE GROUP and REGION – Staff, Web-IDSS^† 2005 - 2006**
Freq (%)² Age Group	Atlantic		Quebec		Ontario		Prairie		Pacific		Canada³
Freq (%)² Age Group	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Includes all inmates with a positive TST result, either newly diagnosed on Initial and Ongoing Negative Assessments, Previous positive on Initial Assessment, and Ongoing Positive Assessments. 2 – Frequency calculated by dividing the number positive by the number of inmates participating in TB screening per age group and region. 3 – LTBI totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=325) and 2006 (N=278)
Missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (25.0%)	1 (10.0%)	1 (33.3%)	3 (15.0%)	0 (0.0%)	0 (0.0%)	3 (15%)	4 (9.1%)
17-19	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
20-29	0 (0.0%)	1 (1.7%)	1 (5.9%)	2 (10.5%)	3 (4.4%)	2 (1.6%)	2 (5.9%)	7 (5.0%)	0 (0.0%)	2 (.4%)	10 (3.3%)	16 (3.6%)
30-39	7 (5.3%)	4 (2.4%)	4 (8.3%)	5 (7.9%)	4 (2.5%)	5 (3.0%)	11 (12.1%)	18 (5.8%)	3 (3.3%)	2 (2.1%)	31 (5.1%)	38 (4.3%)
40-49	10 (6.3%)	14 (6.3%)	9 (20.5%)	10 (11.6%)	2 (1.3%)	7 (5.2%)	11 (16.7%)	30 (9.4%)	4 (4.7%)	5 (8.2%)	41 (7.1%)	74 (8.2%)
50-59	3 (2.6%)	5 (3.7%)	3 (18.8%)	6 (13.6%)	6 (6.1%)	4 (5.0%)	13 (28.9%)	29 (14.1%)	9 (8.7%)	3 (4.8%)	36 (8.5%)	53 (9.0%)
60 +	4 (28.6%)	5 (27.8%)	0 (0.0%)	1 (25.0%)	2 (20.0%)	0 (0.0%)	1 (16.7%)	3 (10.0%)	1 (6.7%)	0 (0.0%)	10 (20.0%)	10 (12.8%)
TOTAL (%)	24 (5.1%)	29 (4.8%)	17 (13.5%)	24 (11.1%)	18 (3.7%)	19 (3.6%)	39 (15.9%)	90 (8.8%)	17 (5.0%)	21 (4.1%)	131 (6.6%)	195 (6.6%)

Top of Page

**Table F.5: LTBI¹ by ORIGIN and REGION – Staff, Web-IDSS^† 2005 - 2006**
Freq (%)² Origin	Atlantic		Quebec		Ontario		Prairie		Pacific		Canada³
Freq (%)² Origin	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Includes all inmates with a positive TST result, either newly diagnosed on Initial or Ongoing Negative Assessments, Previous positive on Initial Assessment, or Ongoing Positive Assessments. 2 – Frequency calculated by dividing the number positive by the number of inmates participating in TB screening per origin group and region. 3 – LTBI totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=325) and 2006 (N=278)
Canadian Born	3 (2.6%)	8 (4.2%)	10 (11.1%)	19 (13.4%)	4 (3.3%)	5 (2.4%)	6 (8.3%)	19 (6.0%)	1 (1.1%)	4 (3.2%)	32 (4.9%)	61 (5.6%)
Aboriginal	0 (0.0%)	1 (16.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (7.7%)	4 (18.2%)	7 (9.9%)	1 (6.7%)	0 (0.0%)	5 (7.7%)	10 (9.2%)
Foreign Born	1 (100.0%)	0 (0.0%)	0 (0.0%)	1 (20.0%)	1 (14.3%)	0 (0.0%)	5 (55.6%)	5 (26.3%)	1 (10.0%)	1 (6.7%)	12 (22.2%)	10 (16.1%)
Unknown	20 (5.8%)	20 (5.0%)	7 (23.3%)	4 (6.2%)	13 (3.7%)	13 (4.4%)	24 (16.9%)	59 (9.6%)	14 (6.1%)	7 (4.8%)	82 (6.7%)	114 (6.8%)
Total (%)	24 (5.1%)	29 (4.8%)	17 (13.5%)	24 (11.1%)	18 (3.7%)	19 (3.6%)	39 (15.9%)	90 (8.8%)	17 (5.0%)	12 (4.1%)	131 (6.6%)	195 (6.6%)

**Table F.6: LTBI¹ by GENDER and REGION – Staff, Web-IDSS^† 2005 - 2006**
Freq (%)² Gender	Atlantic		Quebec		Ontario		Prairie		Pacific³		Canada⁴
Freq (%)² Gender	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006	2005	2006
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Includes all inmates with a positive TST result, either newly diagnosed on Initial or Ongoing Negative Assessments, Previous positive on Initial Assessment, or Ongoing Positive Assessments. 2 – Frequency calculated by dividing the number positive by the number of inmates participating in TB screening per gender and region. 3 – Prior to April 1^st 2004, federally sentenced women in Pacific region were generally kept in a provincial institution. 4 – LTBI totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=325) and 2006 (N=278)
Male	11 (5.6%)	12 (4.4%)	5 (11.1%)	15 (14.3%)	13 (5.3%)	9 (3.1%)	20 (16.3%)	44 (8.4%)	11 (5.7%)	3 (2.0%)	67 (6.9%)	93 (6.4%)
Female	12 (4.6%)	16 (5.1%)	12 (15.0%)	9 (8.4%)	4 (1.9%)	6 (3.2%)	19 (15.8%)	30 (8.5%)	6 (4.3%)	8 (6.7%)	61 (6.3%)	79 (6.5%)
Unknown	1 (14.3%)	1 (5.9%)	0 (0.0%)	0 (0.0%)	1 (3.2%)	4 (7.5%)	0 (0.0%)	16 (10.7%)	0 (0.0%)	1 (4.0%)	3 (5.0%)	23 (8.6%)
Total (%)	24 (5.1%)	29 (4.8%)	17 (13.5%)	24 (11.1%)	18 (3.7%)	19 (3.6%)	39 (15.9%)	90 (8.8%)	17 (5.0%)	12 (4.1%)	131 (6.6%)	195 (6.6%)

Table F.7.i: Reported Comorbidity / Risk Factors¹ and Symptoms¹
by TST Result – Staff, Web-IDSS^† 2005
Test Type	Positive²	Previous Positive³	Ongoing Positive	Sub-Total	Negative	Other⁴	Sub-total	TOTAL
Test Type	N= 42	N= 10	N= 79	N= 131	N= 1,422	N= 446	N= 1,868	N= 1,999
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Numbers in the table reflect those answering 'Yes' to the risk factor / symptom (individuals may report multiple risk factors / symptoms). 2 - Includes newly positive TST results from Initial and Ongoing Negative assessments. 3 – Previously positive TST accepted on Initial Assessment – see Table F.1. 4 - 'Other' result includes medically contraindicated, invalid TST-1, invalid TST-2 (second of two-step TST), refused, and blank/unknown.
Risks
Diabetes	0	1	3	4	31	21	52	56
	(0.00%)	(10.00%)	(3.80%)	(3.05%)	(2.18%)	(4.71%)	(2.78%)	(2.80%)
Hemodialysis	0	0	1	1	0	0	0	1
	(0.00%)	(0.00%)	(1.27%)	(0.76%)	(0.00%)	(0.00%)	(0.00%)	(0.05%)
Silicosis	0	0	0	0	0	0	0	0
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)
Transplant	0	0	0	0	0	1	1	1
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.22%)	(0.05%)	(0.05%)
Injection Drug User	0	0	0	0	6	1	7	7
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.42%)	(0.22%)	(0.37%)	(0.35%)
Lymphoma	1	0	0	1	0	0	0	1
	(2.38%)	(0.00%)	(0.00%)	(0.76%)	(0.00%)	(0.00%)	(0.00%)	(0.05%)
HIV/AIDS	0	0	0	0	7	1	8	8
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.49%)	(0.22%)	(0.43%)	(0.40%)
Chemotherapy	1	0	0	1	2	1	3	4
	(2.38%)	(0.00%)	(0.00%)	(0.76%)	(0.14%)	(0.22%)	(0.16%)	(0.20%)
Oral Steroids	2	0	2	4	23	1	24	28
	(4.76%)	(0.00%)	(2.53%)	(3.05%)	(1.62%)	(0.22%)	(1.28%)	(1.40%)
TB Case Contact	3	0	3	6	38	13	51	57
	(7.14%)	(0.00%)	(3.80%)	(4.58%)	(2.67%)	(2.91%)	(2.73%)	(2.85%)
Total	7	1	9	17	107	39	146	163
Symptoms
Fatigue	1	0	5	6	18	4	22	28
	(2.38%)	(0.00%)	(6.33%)	(4.58%)	(1.27%)	(0.90%)	(1.18%)	(1.40%)
Fever	0	0	1	0	3	1	4	4
	(0.00%)	(0.00%)	(1.27%)	(0.00%)	(0.21%)	(0.22%)	(0.21%)	(0.20%)
Weight Loss	0	0	1	1	6	2	8	9
	(0.00%)	(0.00%)	(1.27%)	(0.76%)	(0.42%)	(0.45%)	(0.43%)	(0.45%)
Loss of Appetite	0	0	0	0	6	2	8	8
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.42%)	(0.45%)	(0.43%)	(0.40%)
Night Sweats	0	0	5	5	14	4	18	23
	(0.00%)	(0.00%)	(6.33%)	(3.82%)	(0.98%)	(0.90%)	(0.96%)	(1.15%)
Hoarseness	2	0	2	4	20	3	23	27
	(4.76%)	(0.00%)	(2.53%)	(3.05%)	(1.41%)	(0.67%)	(1.23%)	(1.35%)
Productive Cough	0	0	3	3	36	10	46	49
	(0.00%)	(0.00%)	(3.80%)	(2.29%)	(2.53%)	(2.24%)	(2.46%)	(2.45%)
Coughing Blood	0	0	0	0	1	2	3	3
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.07%)	(0.45%)	(0.16%)	(0.15%)
Chest pains	0	0	1	1	19	4	23	24
	(0.00%)	(0.00%)	(1.27%)	(0.76%)	(1.34%)	(0.90%)	(1.23%)	(1.20%)
Total	3	0	18	20	123	32	155	176

Top of Page

Table F.7.ii: Reported Comorbidity / Risk Factors¹ and Symptoms¹
by TST Result – Staff, Web-IDSS^† 2006
Test Type	Positive²	Previous Positive³	Ongoing Positive	Sub-Total	Negative	Other⁴	Sub-total	TOTAL
Test Type	N= 59	N= 27	N= 107	N= 193	N= 2,307	N= 451	N= 2,758	N= 2,951
† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS) 1 - Numbers in the table reflect those answering 'Yes' to the risk factor / symptom (individuals may report multiple risk factors / symptoms). 2 - Includes newly positive TST results from Initial and Ongoing Negative assessments. 3 – Previously positive TST accepted on Initial Assessment – see Table F.1 4 - 'Other' result includes medically contraindicated, invalid TST-1, invalid TST-2 (second of two-step TST), refused, and blank/unknown.
Risks
Diabetes	1	0	2	3	71	10	81	84
	(1.69%)	(0.00%)	(1.87%)	(1.55%)	(3.08%)	(2.22%)	(2.94%)	(2.85%)
Hemodialysis	0	1	2	3	1	0	1	4
	(0.00%)	(3.70%)	(1.87%)	(1.55%)	(0.04%)	(0.00%)	(0.04%)	(0.14%)
Silicosis	0	0	0	0	0	0	0	0
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.00%)
Transplant	0	1	0	1	3	0	3	4
	(0.00%)	(3.70%)	(0.00%)	(0.52%)	(0.13%)	(0.00%)	(0.11%)	(0.14%)
Injection Drug User	0	0	0	0	4	0	4	4
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.17%)	(0.00%)	(0.15%)	(0.14%)
Lymphoma	0	0	0	0	6	1	7	7
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.26%)	(0.22%)	(0.25%)	(0.24%)
HIV/AIDS	0	0	0	0	4	1	5	5
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.17%)	(0.22%)	(0.18%)	(0.17%)
Chemotherapy	0	1	2	3	6	1	7	10
	(0.00%)	(3.70%)	(1.87%)	(1.55%)	(0.26%)	(0.22%)	(0.25%)	(0.34%)
Oral Steroids	1	1	2	4	35	4	39	43
	(1.69%)	(3.70%)	(1.87%)	(2.07%)	(1.52%)	(0.89%)	(1.41%)	(1.46%)
TB Case Contact	4	1	8	13	182	31	213	226
	(6.78%)	(3.70%)	(7.48%)	(6.74%)	(7.89%)	(6.87%)	(7.72%)	(7.66%)
Total	6	5	16	27	312	48	360	387
Symptoms
Fatigue	0	1	6	7	43	8	51	58
	(0.00%)	(3.70%)	(5.61%)	(3.63%)	(1.86%)	(1.77%)	(1.85%)	(1.97%)
Fever	0	0	2	2	3	1	4	6
	(0.00%)	(0.00%)	(1.87%)	(1.04%)	(0.13%)	(0.22%)	(0.15%)	(0.20%)
Weight Loss	0	0	0	0	10	4	14	14
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.43%)	(0.89%)	(0.51%)	(0.47%)
Loss of Appetite	0	0	1	1	4	2	6	7
	(0.00%)	(0.00%)	(0.93%)	(0.52%)	(0.17%)	(0.44%)	(0.22%)	(0.24%)
Night Sweats	3	1	1	5	24	10	34	39
	(5.08%)	(3.70%)	(0.93%)	(2.59%)	(1.04%)	(2.22%)	(1.23 %)	(1.32%)
Hoarseness	2	0	4	6	13	3	16	22
	(3.39%)	(0.00%)	(3.74%)	(3.11%)	(0.56%)	(0.67%)	(0.58%)	(0.75%)
Productive Cough	8	0	0	8	34	15	49	57
	(13.56%)	(0.00%)	(0.00%)	(4.15%)	(1.47%)	(3.33%)	(1.78%)	(1.93%)
Coughing Blood	0	0	0	0	3	1	4	4
	(0.00%)	(0.00%)	(0.00%)	(0.00%)	(0.13%)	(0.22%)	(0.15%)	(0.14%)
Chest Pains	2	1	3	6	14	4	18	24
	(3.39%)	(3.70%)	(2.80%)	(3.11%)	(0.61%)	(0.89%)	(0.65%)	(0.81%)
Total	15	3	17	35	148	48	196	231

Appendix G:
Inmate Populations 2005-2006

**Table G.1: Federal Institutions in CSC and Inmate Populations 2005-2006**
Institutions (by Region)	Level of security	Male	Female	General Population		New Admissions
Institutions (by Region)	Level of security	Male	Female	2005	2006	2005	2006
Source: Correctional Service of Canada, Performance Management, 2006. 1 – Recorded in OMS as a being admitted to CSC via a facility other than a federal institution 2 – Includes Millhaven Institution and those in Millhaven Assessment at the beginning of the year.
CSC Total	-	-	-	12,222	13,280	4,798	5,057
Male	-	-	-	11,835	12,835	4,530	4,757
Female	-	-	-	387	445	268	300
Atlantic				1,168	1,292	575	573
Atlantic Institution	Maximum	√		180	212	2	1
Dorchester Penitentiary	Medium	√		345	400	0	0
Nova Institution for Women	Multi-level		√	40	60	38	36
Springhill Institution	Medium	√		379	393	424	433
Westmorland Institution	Minimum	√		167	190	0	0
Other¹				37	56	111	104
Quebec				3,033	3,283	1,055	965
Archambault Institution	Medium	√		366	366	0	0
Cowansville Institution	Medium	√		397	412	1	0
Donnacona Institution	Maximum	√		265	306	0	0
Drummond Institution	Medium	√		299	311	0	0
Federal Training Centre	Minimum	√		214	204	0	0
Joliette Institution	Multi-level		√	69	82	35	39
La Macaza Institution	Medium	√		256	253	0	0
Leclerc Institution	Medium	√		339	508	0	0
Montée Saint-François Institution	Minimum	√		177	197	0	0
Port-Cartier Institution	Maximum	√		177	182	0	0
Regional Reception Centre	Maximum	√	√	263	242	1,018	926
Sainte-Anne-des-Plaines	Minimum	√		131	138	0	0
Special Handling Unit	Ultra Max	√		80	82	0	0
Other¹				0	0	1	0
Ontario				3,191	3,592	1,316	1,379
Bath Institution	Medium	√		313	320	0	0
Beaver Creek Institution	Minimum	√		147	153	0	0
Collins Bay Institution	Medium	√		223	234	0	0
Fenbrook Institution	Medium	√		371	400	10	9
Frontenac Institution	Minimum	√		128	172	0
Grand Valley Institution for Women	Multi-level		√	100	99	74	89
Isabel McNeill House	Minimum		√	3	5	0	0
Joyceville Institution	Medium	√		404	464	1	0
Kingston Penitentiary	Maximum	√		334	333	0	2
Millhaven Institution²	Maximum	√		418	502	1,221	1,255
Pittsburgh Institution	Minimum	√		182	190	0	0
Regional Treatment Centre	Maximum	√		110	129	0	0
Warkworth Institution	Medium	√		543	571	0	0
Other¹				19	20	11	24
Prairie				2,900	3,139	1,348	1,557
Bowden Institution	Med/Min	√		509	544	201	295
Drumheller Institution	Med/Min	√		471	506	258	294
Edmonton Institution	Maximum	√		208	231	39	36
Edmonton Institution for Women	Multi-level		√	100	109	95	86
Grand Cache Institution	Minimum	√		221	223	224	255
Grierson Centre	Minimum	√		27	26	0	0
Okimaw Ohci Healing Lodge	Med/Min		√	18	26	0	6
Pe Sakastew Centre	Minimum	√		25	40	0	1
Regional Psychiatric Centre	Multi-level	√	√	184	175	1	0
Riverbend Institution	Minimum	√		80	75	0	0
Rockwood Institution	Minimum	√		75	96	0	0
Saskatchewan Penitentiary	Medium	√	√	355	390	242	263
Saskatchewan Penitentiary Maximum Unit	Maximum	√		74	73	1	11
Stony Mountain Institution	Medium	√		466	553	257	283
Other¹				60	44	31	27
Pacific				1,779	1,974	504	583
Kwìkwèxwelhp	Minimum	√		42	34	0	0
Ferndale Institution	Minimum	√		127	127	0	0
Kent Institution	Maximum	√		243	217	1	3
Matsqui Institution	Medium	√		224	344	0	0
Mission Institution	Medium	√		269	271	0	0
Mountain Institution	Medium	√		442	442	0	0
Regional Health Centre Pacific	Maximum	√		298	168	0	4
Regional Reception Assessment Ctr.	Multi-level	√		4	92	479	535
William Head Institution	Medium	√		122	120	0	0
Fraser Valley Institute for Women	Multi-level		√	47	52	19	33
Other				8	107	6	8

Previous page | ToC

Common menu bar links

Institutional links

Subjects

Working at CSC

Resources

Proactive Disclosure

INFECTIOUS DISEASE SURVEILLANCE
in Canadian Federal Penitentiaries 2005-2006

Appendix A:
Human Immunodeficiency Virus (HIV)

Appendix B:
Hepatitis C Virus (HCV)

Appendix C:
Hepatitis A (HAV) and Hepatitis B (HBV) Virus

Appendix D:
Sexually Transmitted Infections (STI)

Appendix E:
Tuberculosis Screening - Inmates

Appendix F:
Tuberculosis Screening - Staff

Appendix G:
Inmate Populations 2005-2006

Common menu bar links

Institutional links

Subjects

Working at CSC

Resources

Proactive Disclosure

INFECTIOUS DISEASE SURVEILLANCE in Canadian Federal Penitentiaries 2005-2006

Appendix A: Human Immunodeficiency Virus (HIV)

Appendix B: Hepatitis C Virus (HCV)

Appendix C: Hepatitis A (HAV) and Hepatitis B (HBV) Virus

Appendix D: Sexually Transmitted Infections (STI)

Appendix E: Tuberculosis Screening - Inmates

Appendix F: Tuberculosis Screening - Staff

Appendix G: Inmate Populations 2005-2006

INFECTIOUS DISEASE SURVEILLANCE
in Canadian Federal Penitentiaries 2005-2006

Appendix A:
Human Immunodeficiency Virus (HIV)

Appendix B:
Hepatitis C Virus (HCV)

Appendix C:
Hepatitis A (HAV) and Hepatitis B (HBV) Virus

Appendix D:
Sexually Transmitted Infections (STI)

Appendix E:
Tuberculosis Screening - Inmates

Appendix F:
Tuberculosis Screening - Staff

Appendix G:
Inmate Populations 2005-2006